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Bupleuri radix and Panax quinquefolium were extracted by hot water. 
Water-soluble substances were precipitated by stepwise alcohol precipitation 
based on the molecular size of the substances. Fraction I of Bupleuri radix (BRI) 
and Panax quinquefolium (PQI) were further purified by gel filtration 
chromatography and anion exchange chromatography. 
By gel filtration chromatography, BRI was fractionated into BRIA 
卜60kD) and BRIB (20-30kD); while PQI was fractionated into PQIA (~60kD), 
PQIB (20-30kD), and PQIC (4kD). BRIB and PQIC were found to exhibit TNF 
induction activity. With anion exchange chromatography, the negatively charged 
portion of BRIB - BRIBb and PQIC - PQICb were able to induce higher serum 
TNF activity in a dose dependent maimer. 
These hot-water extracts from Bupleuri radix and Panax quinquefolium were 
rich in carbohydrate. With uronic acid determination by carbazole assay, the 
negatively charged portion of sample were found high in uronic acid content; 
BRIBb had 33% and PQICb had 99.6%. These uronic acid-riched polysaccharide 
exhibited higher TNF inducing activity. 
% 
Acetic acid treatment was employed to remove lipid A in order to study 
whether the samples were contaminated with LPS. There was a significant 
decrease in TNF inducing activity after acetic acid treatment. With carbohydrate 
and uronic acid determination, there was also a decrease in carbohydrate and 
uronic acid content in sample after acetic acid treatment. Since acid hydrolysis of 
sample might occur with acetic acid treatment, depolymerization of 
polysaccharide-riched sample might also cause a decrease in TNF inducing 
• • u 
activity. Thus, acetic acid treatment is not a possible way to remove LPS from our 
samples. * 
Intravenous administration of BRIAb and PQIAb could induce a low level 
of serum TNF activity. This initial activation of macrophage by BRIAb and 
PQIAb could desensitize monocytes/macrophage to become unresponsive to a 
second stimulus, LPS. Pretreatment by BRIAb and PQIAb intravenously failed to 
amplify LPS-induced release, or evenly suppressed UPS-induced TNF release with 
intravenous pretreatment by PQIAb. 
However, BRIA and BRIB subfractions could elicit antitumor activity in 
EAT-bearing mice. BRIBa and BRIBb produced higher EAT cell growth 
suppression (50%), correlating to the higher serum TNF level induced by these 
ft 
samples. In EAT-bearing mice, BRIAb could enhance LPS-induced TNF release 
in serum and ascitic fluid. The EAT cell growth suppression was also enhanced. 
.. • ‘ • • . 
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ADCC antibody -dependent cellular cytotoxicity 
BSA bovine serum albumin 
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FCS fetal calf serum 
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Chapter 1 1 
Chapter 1 Introduction 
1.1 TNF molecule 
As tumor necrosis factor (TNF or TNF-a) comes into history of 
immunology, many investigations have been done on its ability to cause necrosis 
of animal tumors. 
The gene coding for TNF is closely linked to lymphotoxin (also named as 
TNF-6) (Fig 1.1). TNF-a and TNF-B genes locate within the major 
histocompatibility complex region on the short arm of chromosome 6 in humans 
and chromosome 17 in mice. The human TNF gene contains three''introns with 
3 kb long. TNF is first produced as a 26 kD propeptide having 233 amino acid 
residues. This molecule is formed within the cell membrane and exhibit 
bioactivity. Undergoing proteolytic cleavage of a 76 residue signal peptide, a 
soluble form of TNF is secreted. The secreted form consists of 157 amino acid 
residues and contains one intrachain disulphide bond. This 17 kD extracellular 
molecule exists as a trimer in solution to maintain its bioactivity (Rock et oL， 
1991). Once TNF is secreted, it has a circulating half-life of 7 min in mice, and 
14-18 min in humans. (Rock et al., 1991). Most of the secreted proteins are N-
glycosylated, but the secreted form of TNF is non-glycosylated. 
Although lymphotoxin gene is closedly linked to TNF gene and has 30% 
amino acid homology with TNF, they are distinct in their activity. In contrast to 
TNF, lymphotoxin does not code for transmembrane protein. Monocytes and 
macrophages are the major sources of TNF, and lymphotoxin is produced by T 
lymphocytes mainly. However, the production of TNF and lymphotoxin can be 
regulated at the transcriptional level, at the post-transcriptionally control of 
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Figure 1.1 Structure of mouse TNF locus. (Reproduced from Shakhov et 
oL’ 1990) 
mRNA amount, at the translational efficiency, and at the post-translational event 
on the processing of TNF from transmembrane form to a secreted form. 
12 Molecular biosynthesis of TNF 
Lipopolysaccharide (LPS or endotoxin) from gram-negative bacterial cell 
wall is a potent inducer for TNF production. It can stimulate macrophage 
activation and thus trigger TNF release. The promoter sequence of TNF gene 
contains at least four binding sites for NF-KB transcription factor (fig 1.1). NF-KB 
is composed of one 50 kD DNA-binding subunit and one 67 kD subunit of 
unknown function (Jongeneel, 1992). In most cell types, NF-KB forms a complex 
with a 37 kD inhibitor, IKB, in the cytoplasm, thus the binding to DNA is 
prevented. 
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LPS can induce activation of NF-KB and protein kinase C (PKC) activity 
in primary macrophages. In vitro studies evidenced that IKB is a substrate for 
calcium-dependent PKC. Phosphorylation of IKB results in its dissociation from 
NF-KB. Thus NF-KB is activated and binds to TNF promoter to proceed TNF 
gene transcription. 
It has also been evidenced that NF-KB involves in the LPS-indudble 
expression of immunoglobulin K light chain in B lymphocytes. The activation of 
promoters controlling the expression of genes involved in inflammatory responses 
is related to NF-KB activity. Chung et al (1992) recently reported that inhibitor 
of protein kinase C could inhibit IFN-y/LPS-induced TNF expression in a dose-
dependent manner. These data suggested that PKC activity is required for TNF 
gene transcription. Apart from the activation of PKC, induction of phospholipase 
Aj activity and generation of arachidonic acid pathway metabolites, leukotriene 
B4 and prostaglandin £3, are also required for activation of TNF gene expression 
(Horiguchi et al” 1989). 
13 Antitumor activity of TNF 
In vitro 
Depending on the condition of cell culture and cell type, TNF can produce 
antiproliferative activity or growth-stimulatory activities on tumor cells and normal 
cells. 
Most likely, TNF mediates its cytotoxic or cytolytic activity on tumor cells. 
In vitro studies reported that TNF can inhibit the growth of most tumor cell lines 
(about 40%) or even lyse them (Malik et al, 1992). The sensitivity of tumor cell 
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lines to TNF activities is so variable, even some tumor cell lines express TNF 
receptors, they are resistant to TNF cytotoxicity. Murine L929 and WEHI164 cell 
lines are more susceptible to TNF cytotoxicity, they are lysed by TNF in 
concentration of fentomolar range. Because of their high sensitivity to TNF, these 
two cell lines are preferentially used to assay TNF cytotoxicity. Treatment of L 
cells with TNF for 1 to 2 days, the cell growth is inhibited. 
The cytolytic activity of TNF is 1000-fold lower than its cytotoxic activity 
(Baglioni, 1992). It has been reported (Hahn et cd, 1985) that TNF can induce 
‘protective，protein synthesis in the cells to inhibit TNF's cytolytic activity. Several 
tumor cell lines can be protected from TNF-mediated cytolysis by pretreatment 
with TNF. In order to increase sensitivity of tumor cell to TNF, protein synthesis 
inhibitors, such as actinomycin D or cyclohexiimde, are added into tumor cell 
culture with TNF pretreatment. 
The cytotoxic and cytolytic activities of TNF on cell depend on the binding 
of TNF on cell surface receptor. In addition, not all the binding of TNF to its 
receptor can mediate cytotoxicity towards the cell. Some cells are resistant to TNF 
even they can express TNF receptors on their cell surface. Also, there is still no 
correlation between receptor number, or binding affinity and TNF sensitivity. 
Once free TNF binds to its receptor on cell surface, the complex is 
internalized via classic receptor-mediated endocytosis. This binding triggers a 
cascade of second messengers signal to mediate cell response and also regulates 
the TNF receptor expression on cell surface. 
In vitro studies illustrated that TNF mediates its antitumor activity directly 
on tumor cells through these mechanisms (reviewed by Baglioni, 1992): 
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1. Phospholipase A: activation 
TNF can activate phospholipase A! (PLA!) that mediates membrane lipid 
peroxidation (Neale et al, 1988). Phospholipase A � is activated to oxidize 
membrane phospholipids to arachidonic acids. Arachidonic acid is then 
metabolized to form postaglandins and leukotrienes. When L929 cells are treated 
with TNF, there is release of arachidonic acid and its metabolites. These release 
is prior to onset of cell death. TNF cytotoxicity can be abrogated by PLA] 
inhibitor, quinacrine. On the other hand, blockage of arachidonic acid metabolite, 
by treatment with inhibitor of lipo-oxygenase and cyclo-oxygenase, do not 
abrogate TNF cytotoxicity. TNF-mediated cell lysis may not be related to 
arachidonic acid metabolites in a great extent, but PLA] plays an important role. 
2. Free radical generation 
TNF has cytotoxicity effect with mitochondria. It induces intracellular free 
1 
radical generation. Hydroxyl radicals are potent oxidant. Membrane phospholipids 
are peroxidized by free radicals and thus oxidative cell-damage occurs. K has been 
reported that the time course of TNF cytotoxicity in TNF-susceptible cell line is 
related to the generation of intracellular hydroxyl radicals. There was no hydroxyl 
radicals production in TNF-resistant cells. The production of free radicals in cells 
depends on the glutathione content. Reduced glutathione (GSH) is able to 
detoxify oxygen/lipid radical species. Treatment of cells with inhibitors of GSH 
biosynthesis can enhance sensitivity to TNF (Adamson et al, 1992). Also, 
increased intracellular oxidized glutathione can enhance TNF-mediated oxidative 
damage. TNF cytotoxicity can be inhibited by hydroxyl radical scavengers, such 
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as desferroxamine. . 
TNF resistance may also correlate with the TNF and IL-1 induced 
manganese superoxide dismutase (MnSOD) biosynthesis (Wong et al, 1988). 
MnSOD is a mitochondrial antioxidant capable of catalyzing dismutation of 
superoxide radicals. However, overexpression of MnSOD only abrogates TNF-
mediated cytolysis partially. The MnSOD activity is not totally required for TNF 
resistancy in some tumor cell lines. Thus, low radical scavenging capacity 
(increased intracellular oxidized glutathione), rather than the basal level of 
MnSOD, is the major factor for TNF-mediated oxidative damage in cells. 
3. Protease and DNA damage (reviewed by Malik et al” 1992) 
It has been shown that TNF cytotoxicity could be inhibited by protease 
inhibitors. More recent studies indicated that L cells were protected from TNF 
cytotoxicity by serine protease inhibitors (Ruggiero et al” 1987). These data 
indicated that serine protease is involved in TNF cytotoxicity. L cells were also 
protected from TNF-induced cytolysis by B-glucuronidase inhibitor. 6-
glucuronidase is a lysosomal enzyme, therfore, lysosomal enzyme might be 
involved in TNF-induced cytotoxic effect. 
DNA strand damage is also observed in TNF-treated L929 cells. There are 
two mechanisms being proposed for DNA strand damage: (1) free radical-induced 
damage, and (2) activation of endonucleases. Free radicals, such as hydroxyl 
radicals, are generated by TNF-mediated phospholipid peroxidation. Although 
there is no evidence showing direct activation of intracellular endonuclease by 
TNF, TNF cytotoxicity could be abrogated by Zn^" ,^ an inhibitor of endonucleases. 
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In vivo 
The above mechanisms are the direct action of TNF on tumor cell itself. 
Antitumor activities of TNF also depend on the tumor type, tumor site, tumor 
size, stage of tumor development, and route of TNF administration. The effective 
route of TNF administration is local, in or near the tumor, intratumoral 
application of TNF is the most effective (Balkwill, 1989). During tumor growth, 
there is development of tumor vasculature for blood vessels to nourish tumor. 
Thus, by intravaneous administration, TNF can be carried to tumor site. TNF 
exerts its cytotoxic effect on tumor vasculature. It causes endothelial cells to 
produce tissue factor that favouring intravascular coagulation. Therefore, necrosis 
of vessels within tumors occurs. TNF also mediates hypotension, such that 
perfusion of oxygen and other bioactive substances is reduced in highly vascular 
area. Since there is necrosis of blood vessels that nourish tumors, tumor cells then 
ft 
starve and die. Evidence also suggested that well-established tumor is susceptible 
to TNF-mediated hemorrhagic necrosis (reviewed by Malik et al, 1992). These 
results were done using Meth A as a model because it is a classical tumor used 
for studying antitumor effects of TNF. In vitro culture of Meth A, intraperitoneal 
and early Meth A tumors were resistant to TNF cytotoxic effects. Development 
of tumor vasculature might be essential for TNF-mediated hemorrhagic necrosis 
(Fig 1.2). 
Martinet et al. (1992) reported that there was accumulation of 
macrophages at the tumor sites. Macrophages were recruited from circulating 
blood monocytes through the release of chemotactic factors. These factors, being 
produced by cancer cells, induced the migration of macrophages to tumor sites, 
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Figure 1.2 TNF exhibits antitumor activity by several mechanisms. 
(Reproduced from Wakefield et al” 1991) 
through the concentration gradient of chemotactic factors between the tumor site 
and blood vessels. Monocyte chemotactic activity (MCA) and concentration 
gradient of MCA were detectable between tumor site and blood vessels. The 
accumulation of macrophage at tumor site can upregulate the TNF production. 
TNF can activate macrophage to release more TNF in an autocrine fashion. TNF 
can also mediates its cytotoxic effect through activation of other immune effector 
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cells, such as tumoricidal macrophages, cytotoxic T cells, natural killer cells and 
neutrophils. 
TNF can stimulate the expression of adhesion proteins, E-selectin (ELAM-
1) and intracellular adhesion molecule-1 (ICAM-1) by endothelial cells. These 
proteins have chemotactic activities to attract the neutrophil emigration to the 
sites of tissue injury. In inflammatory site or tumor site, TNF enhances neutrophil 
adhesion to endothelium, neutrophil then exerts its respiratory burst response 
(release of superoxide anion, and hydrogen peroxide H2O2 (Zhang et al； 
1992). 
1.4 Macrophage-mediated immunity 
Macrophages play an important role in cell-mediated immunity. It has been 
found that macrophages have capacity in : (1) phagocytosis and destruction of 
micro-organisms; (2) chemotactic movement along a concentration gradient of 
chemotactic factor; (3) antigen processing and presentation; (4) secretion of 
bioactive substances including lysosomal enzymes, complement component, 
% 
reactive oxygen intermediates (e.g. superoxide, hydrogen peroxide, and hydroxyl 
groups), arachidonic acid intermediates, coagulation factors; and (5) secretion of 
cytokines (e.g. IL-1, TL-6, TNF-a) (Auger et al, 1992). Apart from microbicidal 
function of macrophages, its tumoricidal function is worthy of study. Macrophages-
mediated tumor cytotoxicity (MTC) makes the host to defend against tumors 
independent of antibody production (Fig 1.3). 
Macrophage activation for MTC involves several stages. At the 
inflammation sites, immature mononuclear phagocytes are 'responsible, to 
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Figure 1.3 Mechanisms of tumor cell control by macrophages. (Reproduced 
from Auger et al, 1992) 
inductive signals. Macrophage-activating factor (MAF), such as interferon gamma 
(IFN-Y), can induce ‘responsive，macrophage to ‘primed stage，. At this stage, 
macrophages are still unable to kill tumor cells, but they are ready to be activated 
by trace amount (ng/ml) of LPS. When macrophages are 'fully activated', there 
are markedly increase in secretion of cytolytic proteinase (CP) and TNF. Also, 
macrophages have ability to bind neoplastic tumor cells only when they are 
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primed or activated. This binding ability helps macrophage to recognize tumor 
cells and then release toxic substances for cytolysis of tumor cells. 
Antibody-dependent cellular cytotoxicity (ADCC) also allows macrophages 
to lyse antibody-coated tumor cells. Experimental studies evidenced that 
monoclonal antibodies against tumor cells surface antigens could enhance 
macrophage cytotoxicity. The antibodies act as opsonins to mediate binding of 
tumor cell to macrophages. Macrophages have surface receptors which can bind 
Fc portion of immunoglobulin molecule that are bound to tumor cells surface 
antigen through its Fab portion. The linking of tumor cell to Fc receptor through 
antibody mediates the secretion of lytic mediators (e.g. hydrogen peroxide, 
complement, protease, and TNF) by macrophages, and thus cytolysis occurs. 
ADCC may either rapidly complete over 5 to 6 hr, or slowly over 1 to 2 days. In 
contrast, MTC occurs slowly, it takes over 1 to 3 days to complete (Auger et al, 
1992). 
、 
1.5 Endogenous production of TNF 
Endogenous production of TNF involves the primed stage and triggered 
stage at the molecular level. These two stages occur dependent on the stages of 
macrophage activation. At the primed stage, there is transcription and translation 
of precusor TNF. Precusor TNF is expressed and integrated on the membrane of 
macrophages. Only a negligible amount of soluble TNF is secreted out of the cell. 
However, when the primer is exhausted, this stage returns to normal. At the 
triggered stage, protease is stimulated by stimulus to trigger the proteolysis of 
precusor TNF to release soluble bioactive form of TNF. Trigger, such as LPS, 
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Figure 1.4 Possible mechanism of priming and triggering on TNF 
production in macrophage. (Reproduced from Mizuno, 1992) 
usually is a strong lysosome labilizer to trigger release of lysosomal enzyme from 
lysosome. Normally, TNF mRNA may not be translated unless the cells are 
stimulated by primer, such as IFN-y (Mizuno, 1992) (Fig 1.4). 
There are three types of primer : (1) IFN-y type; (2) particle type; (3) 
delayed type (Table 1.1). 
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Table 1.1 Classification of types of primer. 
I IFN-Y type IFN-y (MAF) , IFN-a, IFN-p, 
IL-2, TNF, LPS, etc. 
II Particle type Polystyrene latex 
Glass beads, OK-432, lentinan, etc. 
III Delayed type BCG, C. parvum, etc. 
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Figure 1.5 Types of priming reaction. (Reproduced from Mizuno, 1992) 
The primed stage stimulated by IFN-y type can reversibly return to normal. In 
other words, it only take several hours to render macrophages to reach the 
primed stage ready for TNF secretion. The second type of primer returns to 
normal stage a bit later. Delayed type requires long period, several weeks, to 
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make macrophages to reach its optimal sensitivity (Fig 1.5). 
LPS is a potent trigger of TNF production. As mentioned before in this 
chapter, LPS induces NF-KB and PKC activities in primary macrophages, and thus 
trigger TNF gene transcription. Binding of LPS to macrophage receptors also 
triggers a cascade of second messengers to mediate proteolytic enzyme activities. 
Transmembrane form of TNF is then cleaved to release soluble mature TNF. 
Pretreatment with primer can enhance LPS-induced TNF secretion by 
macrophages. IFN-y is a potent primer that is currently studied for TNF 
production. Treatment with IFN-y can render macrophages to be more sensitive 
to very low amount of LPS. However, the degree of amplification in endogenous 
LPS-induced TNF release depends on the interval between administration of 
primer and trigger. For example, the optimal time for IFN-y to sensitize 
macrophages to primed stage readily for TNF release is 3 hr (Mizuno, 1992). 
1.6 LPS : a potent inducer of TNF release 
LPS is composed of a polysaccharide domain covalently linked to a 
diglucosamine based acylated phospholipid, lipid A (Fig 1.6). The polysaccharide 
portion of LPS varies in different strains of gram-negative bacteria. The 
polysaccharide portion of LPS is mainly divided into inner and outer core sugars. 
The inner core consists of a unique structure, 2-keto-3-deoxy-octulosonic acid 
鲁 
(KDO), which is covalently linked to lipid A. The outer core structure is variable. 
O-antigen oligosaccharide is an immunochemical variant, which is usually linked 
to the outer core (Raetz, 1990). O-antigen possesses the immunogenicity of LPS, 
this allows the recognition by phagocytes. Most of the biological effect of LPS is 
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Figure 1.6 Covalent structure of E.coli lipid A. (Reproduced from Raetz, 
1990) 
mediated by the lipid A component. Lipid A could induce mitogenic activity in 
B cell (Skidmore et al, 1975) and TNF production (Ha et al, 1985). The structure 
of lipid A is highly conserved among different strains of gram-negative bacteria. 
The backbone of lipid A is 2,3-diacylglucosamine diphosphate with two amide and 
two ester-linked 3-OH-myristate groups. These groups are acylated with two or 
ft 
three fatty acids in E. coli and Salmonella lipid A. Lipid IVA, disaccharide 
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precusor of lipid A, can induce partial activities of lipid A, while monosaccharide 
precusor of lipid A, lipid X，acts as an antagonist to inhibit the action of LPS 
(Lynn et al, 1992). 
Intravaneous administration of LPS into mice can give a peak with 
maximal TNF level within 90 min to 120 min. TNF level then returns to basal 
noninduced levels after 4hr (Sharma etaL,l992). The biosynthesis and processing 
of TNF had also been studied in the murine macrophage-like cell line Raw 264.7 
(Jue etaL,1990), With in vitroUPS stimulation on Raw 264.7cells, cell-associated 
TNF activity could be detected after Ihr. The secreted TNF activity increased 
continuously up to 16hr. It had been evidenced that the nonglycosylated mature 
17kD TNF is secreted earlier than the glycosylated forms. In the activation of 
macrophages, transmembrane bound TNF precusor is cleaved proteolytically to 
secrete mature TNF into the medium. However, there is still a certain amount of 
cell-associated TNF present on the surface of activated macrophages for cell-cell 
communication. This can increase the local TNF concentration on target cells that 
are in close contact with activated macrophages. 
There are two.types of LPS receptors (reviewed by Lynn et al” 1992). It 
had been evidenced that several cellular receptors may be involved in the 
activation by LPS. Some of them are responsible for activation of cells by LPS, 
some can uptake and detoxify free LPS, and some can attach the whole Gram-
negative organisims to phagocyte. A 73 kD LPS-binding protein was also 
identified on the surface of immune splenocytes by using a radio-iodinated 
photoactivatable LPS probe. 
The second type of LPS receptor is CD 14. CD 14 is a 55 kD antigen 
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present on monocyte* and macrophages. It can bind complexes of LPS and 
lipopolysaccharide-binding protein (LBP) and thus mediates macrophage 
activation. Anti-CD 14 monoclonal antibodies could prevent synthesis of TNF by 
whole blood, even in the presence of increasing LPS concentration (Wright etal” 
1990). CD 14 links to the cell surface via a phosphatidyl isonitol anchor (PI) and 
makes its mobility in the plane of the membrane (reviewed by Schumann, 1992). 
It was also supposed that CD 14 may associate with protein tyrosine kinase and 
thus mediates signal transduction. 
LBP is an 50-kD acute phase protein produced in hepatocytes. It has high 
affinity (Kd « lO'^ M) to lipid A moiety of LPS. Once LPS, in soluble form or 
鲁 
present on bacterial cell wall, enters into the circulation, it rapidly binds to LBP. 
LBP then serves as an opsonin to facilitate the attachment of LPS or bacteria to 
CD 14 antigen on membrane of monocytes and macrophages. It does not bind to 
the CD 14 molecule only in complex with LPS. 
At normal stage, LBP is secreted into the plasma at a concentration of 
500ng/ml. In the acute phase of infection or entry of LPS into circulation, serum 
LBP concentration rises to SOMg/ml. When macrophages are exposed to LPS in 
the presence of LBP, macrophage activation is stimulated as a consequence of 
binding of LPS-LBP complex to CD 14 (reviewed by Schumann, 1992). It was 
evidenced that LBP could increase the rate and production of LPS-induced TNF 
production (Mathison era/., 1992). The threshold of LPS required to induce TNF 
release is lowered in the presence of LBP. Thus, LBP functions as an opsonin 
enabling the macrophages or monocytes to detect small amount of LPS, therefore 
triggering the defence cascade. Even in the presence of large amount of LPS, 
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addition of anti-LBP antibodies caused a suppression in TNF release from 
monocytes (Heumann et al., 1992). This evidence suggested that interaction of 
LPS-LBP complex with CD 14 on monocytes is important for cell activation and 
TNF release. 
1.7 Natural product : as primer or inducer 
Endogenous TNF production induced by administration of various 
biological response modifiers and bacterial preparation have been studied. 
Intravanous administration of heat-killed bacterial preparations of Streptoccus 
pyogens (OK-432) or Lactobacillus casei (LC) elicited endogenous TNF production 
in mice. Studies have reported that natural lignins (Frs. VI and VII), PSK, and 
glucans (Schizophyllan and DMAE-paramylon) were potent primers of 
endogenous TNF production. These products are polysaccharides having high 
molecular weight. Pretreatment with these high molecular weight polysaccharides 
(Table 1.2) could enhanced OK-432- or LC-induced TNF production 
endogenously (Sakagami et al” 1992). 
Takahaki et al. (1987) have also reported that intravaneous administration 
of polysaccharide, MGA, could induce TNF-like cytotoxic factor into tumor 
tissues. MGA is monoglucans prepared from the actinomycetes Microellobosporia 
grisea. These monoglucans have molecular weight about 300-1000kD, and have a 
tetrasaccharide repeating-unit structure. 
Zymosan, which is prepared from carbohydrate-rich cell wall of yeast 
Saccharomyces cerevisiae, was found to have priming activity of endogeous TNF 
production (Wong, 1990). This product consists of two polysaccharide 
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Table 1.2 Properties of different bacterial preparations 
molecular … … ； 如 
weight properties 
heat-killed bacterial preparations of 
OTC 
Streptococcus pyogenes 
heat-killed bacterial preparations of 
LC Lactobacillus casei 
protein-bound polysaccharide 
PSK 50-200kD hot water extract of mycelia of Coriolus 
versicolor 
…^ prepared from filtrate of cultured 
Schizophyllan _ O k D "schizophyllum Commune 
N,N-dimethyl-aininoethyl derivative of 
DMAE- 1 ” ⑷ paramylon 
paramylon water extract-insoluble (l-3)-S-glucan 
prepared from Euglena gracilis 
”A n prepared from alkaline extract of the cone 
natural lignins 70-200kD ^ 具—pa rv i f l o r a 
(Sakagami et al” 1992) 
components, aD-maiman and SD-glucan. It was believed that zymosan can bind 
to the mannose/fucose receptors, the S-glucan receptors, and the CD11/CD18 
molecules on macrophages or monocytes. The binding of zymosan on these 
macrophage receptors is direct interaction without opsonization. The binding of 
zymosan particles on macrophage enable it to elicit cell responses (Sung et al, 
1983). 
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1.8 Aim of this project 
The aim of this research is to investigate the endogenous TNF production 
by two Chinese medicinal herbs, Bupleuri radix and Panax quinquefolium. 
Traditional Chinese medicinal herbs are used in chemotherapy for many years. 
It is believed that Chinese herbs have ability to restore immune response to the 
normal stage or somehow enhance the immunological activity. 
In Chinese herbal medicine, Bupleuri radix (Chai Hu) is used as an 
antipyretic agent. Antipyretic agent exhibits an effect to lower body temperature 
towards normal level, achieved by vasodialation and sweating. This herb is 
commonly used for children and pregnant women, suffer from common cold, 
influenza, and malaria. For infectious disease with fever, Chai Hu can bring body 
temperature towards normal level, without recurrences. This herb also has 
sedative and analgesic actions. Thus, it has been used as an antibacterial and anti-
malaria agent (Huang, 1993). 
Bupleuri radix is one of the component used in traditional Chinese 
medicines, Xiao-chai-hu-tang. This medicine is used because of its anti-
inflammatory effect. The anti-inflammatory and immune effects of Xiao-chai-hu-
tang might mainly come from the action of Bupleuri radix. Pretreatment with 
Xiao-chai-hu-tang could prevent the side effects of TNF and LPS, without 
impairment of antitumor activity of TNF and LPS (Satomi et al, 1989). TNF 
induces prostaglandin production, and further oxygen radicals. Xiao-chai-hu-tang 
was able to decrease prostaglandin level. 
Haranaka et al (1985) reported that aqueous crude extract of certain 
traditional Chinese medicines exhibited anti-tumor activities and TNF 
會 
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producibility. Mice were treated with various drugs by oral administration for two 
weeks, followed by LtS injection. It was reported that treatment with Bupleuri 
radix exhibited a relatively high serum TNF activity. The survival rate of tumor-
bearing mice treated with this herb was increased. 
Ginseng is the most valuable herb used in China, Japan, Korea, and even 
in America. It has been used as a tonic and emergency medicine to rescue dying 
patients, and as a rejuvenating and revitalizing agent. Different species of ginseng 
were found in China, Korea, Japan, and North America. Scientists had paid 
attention to the study of ginseng. These studies included chemical structure of 
venous species of ginseng, pharmacological actions and clincal applications of this 
herb. It had been studied that ginseng had several pharmacodynamic actions, on 
cardiovascular system, central nervous system, endocrine system, metabolism, and 
immune system. This herb also exhibited anticancer, antiaging and anti-
inflammation activities (Huang, 1993). 
In the present project, Panax quinquefolium (Shi-yang Seng or American 
ginseng) was studied. This kind of ginseng was collected from the North America's 
Appalachian mountains. 
Water extract from Bupleuri radix and Panax quinquefolium were purified 
into several subfractions by alcohol precipitation, gel filtration chromatography, 
and anion exchange chromatography. The priming and eliciting activity on 
endogenous TNF production were studied. 
Chapter 2 22 
Chapter 2 Materials and Methods 
2.1 Materials 
Sephadex G-lOO, and dextran with average molecular weight of 66700, 
38900, 9500, and 5000 were purchased from Pharmacia Co. Ltd. 
Lipopolysaccharide oi Escherichia coli 0127:B8, RPMI 1640 (suppplemented with 
25mM HEPES), trypan blue, DEAE-Sephadex, and benzolated dialyzing tube 
(with molecular weight cutoff value of 1200) were purchased from Sigma Co. Ltd. 
Fetal calf serum (FCS) was obtained from Gibco. Murine TNF-o: ELISA kit and 
murine TNF-a standard were purchased from Genzyme Co.Ltd. (Cambridge, 
MA). 75cm^ culture flask was obtained from Corning Co., and 96 well flat-
bottomed culture plate was obtained from Nunc Co. 
2.2 Animals 
、 
ICR mice were obtained from Animal House, the Chinese University of 
Hong Kong. Male ICR mice weighing 30-38g were used. They were kept，10 
animals per cage, in a temperature- (25°C) and humidity-controlled room, and fed 
with standard laboratory chow and tap water. 
2.3 Cell Line 
Murine fibroblast cell line L929 was obtained from American Type Culture 
Collection (ATCC, Rockville, MD). Cells were maintained in a 75cm^ plastic 
tissue culture flask containing complete medium (supplemented with 5% FCS) at 
37°C in a humidified atmosphere containing 5% CO� in air. The cells were 
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allowed to grow until a monolayer was formed. It took about 3 to 4 days. L929 
cells could be harvested by trysinization with 1ml of trysin. Cells were then 
washed with plain RPMI medium and resuspended in complete medium for 
continuous culture or assay. 
2.4 Transformed cell line : EAT cells in vivo 
Erchlish ascitic tumor (EAT) cells were maintained in ICR mice. EAT 
cells (107) in 0.2ml of PBS were injected ip into the mice. After 7 days, mice were 
killed by cervical dislocation. EAT cells in ascitic form were collected by 
exhaustive drainage and washed with half-PBS to remove red blood cells. The 
cells were then washed with PBS twice. The cell number was counted by trypan 
blue exclusion with use of hemocytometer. Finally, cell number was adjusted to 
5x10^ cells/ml in PBS. Weekly passage of EAT cells was required. 
2.5 Reagents 
Culture medium 
RPMI 1640 (supplemented with 25mM HEPES) was dissolved in double 
distilled water. For each litre of medium，2g of NaHCOj was added. The medium 
was sterilized by means of filtration through a 0.22iLtm millipore membrane filter. 
For L929 cell culture, complete medium was prepared by supplementing the plain 
medium with 50 units/ml of penicillin, 50 Mg/ml of streptomycin, 0.3% (w/v) 
glucose, 0.03% (w/v) L-glutamine, and 5% (v/v) FCS. For in vitro TNF 
cytotoxicity, heat inactivated FCS (HIFCS, 56°C, 30min) was used instead of FCS. 
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Phosphate Buffered Saline (PBS) 
PBS contained 140mM of NaCl, 2.7mM of KCl, 1.5mM of KH2PO4, and 
S.lmM of NazHPO*. The pH value was adjusted to 7.4. Half-PBS was prepared 
by 2 folds dilution of PBS with distilled water. 
Normal Saline 
Normal saline was prepared by dissolving 0.9g of NaCl in 100ml of distilled 
water to give a final concentration of 0.9% (w/v). 
Neutral Red (0,05%) 
Neutral red (BDH, 0.5g) was dissolved in 100ml of normal saline. The 
mixture was then filtered through Whatman No.l filter paper to remove insoluble 
substances. 
Trypan Blue (0.3%) 
Trypan blue (0.3g) was dissloved in 100ml of PBS. Insoluble subtances 
were removed by filtration through Whatman No.l filter paper. 
2.6 Methods 
In vitro assay for TNF activity 
TNF activity was measured by its cytotoxicity towards L929 cells. L929 cells 
were plated in 96 well flat-bottomed culture plate at a density of 4x104 cells per 
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well in lOOjLtl of complete medium containing 5% of HIFCS. Cells were cultured 
at 37°C under 5% CO2 in humidified atmosphere. After 18h for cell adhesion, the 
medium was aspirated out. Serially diluted test sample in lOO/xl of 5% HIFCS 
complete medium (containing 10/xg/ml of cycloheximide) was added to each well. 
After 24h incubation at 37°C with 5% CO2 in air, the viability of L929 was 
measured by staining the viable cell with neutral red. The cell supernatant was 
aspirated. 50/xl of neutral red (0.5% in normal saline) was added to each well and 
the plate was incubated at 37。C for Ih. Neutral red was then aspirated out and 
the plate was washed with PBS (~200jLtl per well) twice. The plate was then dried 
at 60。C in an oven overnight. The cells which had uptaken the dye were dissolved 
by adding lOOjLtl of 1% SDS (w/v) into each well. Absorbance was measured by 
an ELISA reader (Titertek Uniskan, Flow Laboratory) at wavelength of 540iim. 
The percentage of cytotoxicity was calculated by the following equation : 
percentage of cytoxicity = (C-T)/C x 100 
where C is the absorbance of wells of L929 cells cultured with control sample, 
and T is the absorbance of wells of L929 cells cultured with test sample. One unit 
of TNF activity is defined as the amount of TNF producing 50% of cytotoxicity. 
Murine TNF-a (Genzyme) was applied as standard control. The sensitivity of this 
in vitro assay was limited to 200pg/inl. 
Murine TNF-oi ELISA kit 
Murine TNF-a ELISA kit was purchased from Genzyme Co. (Cambridge, 
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MA). The sensitivity of this kit was limited to lOOpg/ml. 
Determination of carbohydrate content 
Carbohydrate content was determined by the phenol-sulphuric acid method 
(Chaplin, 1986). Samples, standard, or blank(200/xl) was mixed with 200m1 of 5% 
phenol solution (v/v). Concentrated sulphuric acid (1ml) was added directly and 
rapidly into the tube. The solution was left undisturbed at room temperature. 
After lOmin，the solution was shaken vigorously. The absorbance was measured 
at 490nm after 30min. The sensitivity of this method ranges from 30mM to 2mM. 
Dextran with molecular weight of 66700, 38900，9500，and 5000 were used as 
standard. 
Determination of protein content 
Protein content was measured by the Lowry method (Lowry et al, 1951). 
Four kinds of reagent were required : (1) solution A - 2% Na2C03 (w/v) 
dissolving in O.IM of NaOH; (2) solution B^ - 1% CUSO4 (w/v); (3) solution B]-
2% sodium/potassium tartrate (w/v); (4) Folin-Ciocalteu's phenol reagent 
(Merck) diluted 2-fold with distilled water before use. Before the assay, solution 
A, Bi, and B�were mixed in a ratio of 100:1:1 (solution Bj and B] were mixed 
first) to give solution C. Solution C (1ml) was mixed with 200^1 of blank, 
standard, or samples. BSA was used as protein standard. The mixture was allowed 
to stand at room temperature for lOmin. Diluted Folin reagent (lOOjLtl) was added 
and the mixture was allowed to stand at room temperature for a further 30min. 
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Absorbance was read at wavelength 750nm against reagent blank. 
Determination of uronic acid content 
Carbazole assay (Chaplin, 1986) was employed for determination of uronic 
acid. Two reagents were prepared : (1) reagent A - 0.95g of sodium tetraborate 
decahydrate was dissolved in 2ml of hot-water, and 98ml of ice-cold concentrated 
sulphuric acid was added carefully with stirring; (2) reagent B _ 125mg of 
carbazole (recrystallized from ethanol) was dissolved in 100ml of absolute ethnol. 
The above two reagents were kept stable in refrigirator. During the assay, 1.5ml 
of ice-cold reagent A was mixed with 250/xl of ice-cold blank, standard, or sample 
with stirring and cooling in the ice-bath. The mixture was heated at 100°C for 10 
min. After heating, the mixture was cooled rapidly in ice-bath. Reagent B (SOfil) 
was then added with well mixing. The mixture was reheated at 100°C for 15min. 
After heating, the mixture was cooled to room temperature, and the absorbance 
was read at 525nm. a-D-galactouronic acid was used as standard. The sensitivity 
of this assay ranges from 4 to 400/xM. 
Preparation of samples 
Bupleuri radix (200g) was washed with distilled water and heated at 90。C 
for 4h. After extraction, the supernatant was obtained by centrifagation at 
12000rpm for Ih. Water soluble crude substances were extracted by adding 9 
volumes of 95% ethanol to the supernatant with stirring, to give a final 
concentration of 85.5% ethanol. The above was allowed to stand at 4。C overnight. 
Precipitate was obtained by centrifugation at 12000rpm for 90min. The pellet was 
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air dried and dissolved in a small amount of water. The resultant solution was 
lyophilized and substance obtained was designated as 'BR crude，. 
Bupleuri radix crude extract was fractionated by stepwise alcohol 
precipitation. BR crude (3g) was dissolved in 100ml of distilled water. Insoluble 
substance was removed by centrifugation at 2000rpm for 5imn. Equal volume of 
95% ethanol was added to the supernatant with continuous stirring. The mixture 
was kept at 4°C overnight. The precipitate was obtained by centrifugation at 
12000rpm for 90min. The pellet obtained was air-dried, redissolved and 
lyophilized. The dried substance obtained was designated as BRO. The 
supernatant were further sujected to the above procedure of stepwise alcohol 
precipitation. The supernatant obtained in each step was mixed with equal volume 
of 95% ethanol. The precipitate was obtained by centrifugation and followed by 
lyophilization. The pellets obtained in each steps were designated as BRI, BRII, 
BRin, and BRIV respectively. 
Gel Chromatography 
Samples were separated by Sephadex G-lOO according to their molecular 
size. Sephadex G-lOO (42g) was mixed with 1 litre of distilled H p and kept at 
4。C for 4 days for gel swelling. XK50/100 column (5x89cm, Pharmacia) was 
packed with the above degassed Sephadex G-100. The column was equilibrated 
with degassed distilled H2O. Samples (800mg) was dissolved in distilled H2O 
(lOOmg/ml) and applied onto the column. The column was eluted with degassed 
distilled H2O. Fractions of 10ml (per 30min) were collected and analyzed by the 
phenol-sulphuric acid method. The eluates obtained at the peak of carbohydrate 
• . 
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content were pooled, concentrated and lyophilized. Dextrans having known 
average molecular weight were run on the column to obtain a calibration curve 
for molecular weight determination. 
Anion Exchange Chromatography 
Anion exchange chromatography was employed to isolate negatively 
charged carbohydrates from the sample. 
Preparation of salt phosphate buffer : 
1. lOmM NaCl phosphate buffer 
solution A : lOmM NaCMOmM Na2HP04 
solution B : lOmM NaCMOmM NaHzPO* 
lOmM NaCl phosphate buffer was prepared by adding solution B into 
850ml of solution A with continuous stirring, until pH value was adjusted to 8. 
2. 500mM NaCl phosphate buffer 
solution C : 500mM NaCMOmM Na2HP04 
solution D : 500mM NaCMOmM NaHaPOj 
500mM NaCl phosphate buffer was prepared by adding solution D into 
850ml of solution C with continuous stirring, until pH value was adjusted to 8. 
3. IM NaCl phosphate buffer 
solution E : IM NaCMOmM Na^HPOi 
solution F : IM NaOlOmM NoHzPOa 
IM NaCl phosphate buffer was prepared by adding solution F into 850ml 
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of solution E with continuous stirring, until pH value was adjusted to 8. 
DEAE-Sephadex (Ig) was swelled in 300ml of lOmM NaCl phosphate 
buffer and kept at 4。C overnight. The gel was then packed into a 2xl5cm glass 
tube. The column was equilibrated with lOmM NaCl phosphate buffer. Sample 
(150mg) was dissolved in lOmM NaCl phosphate buffer at a concentration of 
lOOmg/ml, and then applied to to the column. The column was initially eluted 
with lOmM NaCl phosphate buffer. Fractions of 7ml (per 7min) were collected 
and analyzed by the phenol-sulphuric acid method. When the absorbance at 
490nm became undectectable and leveled off, the column was then eluted with 
500mM NaCl phosphate buffer. When the carbohydrate content became 
undetectable, the column was finally eluted with IM NaCl phosphate buffer, 
Fractions eluted at different concentration of salt phosphate buffer was dialyzed 
against distilled water. The dialyzing tube being used have a molecular weight 
cutoff value of 1200. The dialyzing water was changed twice everyday until the salt 
content in the sample became undetectable. The presence of salt in sample 
solution was determined by precipitation with 1% AgNOg. Equal volume of 
sample solution was mixed with 1% AgNOj, the presence of white precipitate 
indicated the presence of salt. After dialysis, the solution was lyophilized. 
Removal of LPS by acetic acid treatment 
Sample (lOmg) was dissolved in 5ml of distilled H2O. Equal volume of 2% 
acetic acid was added and mixed well. The mixture was heated at 100°C for 
90min. After heating, the mixture was cooled to room temperature. Due to acid 
hydrolysis of LPS, lipid A precipitates out and was removed by centrifugation at 
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SOOOrpm for 5min. The supernatant was dialyzed against distilled water. The 
dialyzing tube being used have a molecular weight cutoff value of 1200. Dialyzing 
water was changed twice everyday. Sample solution was then lyophilized. 
Collection of serum 
Mice were anaesthetized in a atmosphere containing ether. Mice were bled 
from their subclavin vessel to obtain blood. The blood was allowed to coagulate 
at room temperature. After coagulation, serum was separated immediately by 
centrifugation at 2000rpm for 15min. Serum was inactivated at 56°C for 30min. 
Aliquots of heat-inactivated serum were stored at -70°C for TNF activity 
determination by in vitro L929 cell bioassay and murine TNF-a ELISA kit. 
Endogenous TNF production in mice 
Samples were dissolved in PBS at a concentration of 
2mg/0.2nilPBS/mouse. Mice were treated with iv injection of the test sample. 
After 30min to 6h, mice were bled to collect serum for TNF activity 
determination. Samples with concentration ranging from 100/xg to 2mg were used. 
LPS control was performed by iv injection of 25/xg of LPS {Exoli 0127:B8), 
in 0.2ml of PBS, into mice. After 30min to 6h, blood was bled to collect serum for 
TNF activity determination. 
Antitumor effect of sample in EAT hearing mice in relation to TNF production 
1. priming effect 
EAT bearing mice were killed by cervical dislocation. EAT cells were 
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harvested by exhaustive drainage and washed with half-PBS. The cell number was 
adjusted to IxlOVml in PBS. ICR mice (10 in group) were inoculated with ip 
injection of 0.2ml cell suspension (2x10^ cells per mouse) on day 0. On day 1， 
5mg of sample in 0.5ml of PBS was injected ip into the mice. On day 7，mice were 
treated with 25ptg of LPS by iv injection. After 90min of LPS injection, mice (3 
per group) were bled to collect serum. Ascitic fluid was collected simultaneously. 
Both the serum and ascitic fluid were heat-inactivated at 56°C for 30min. Aliqouts 
were stored at -70°C for TNF bioactivity determination. After 2 days, EAT cells 
in the remaining mice of each group were collected and counted by trypan blue 
exclusion method with use of hemocytometer. Total cell number in mouse was 
calculated. PBS was injected (ip and iv) as negative control. 
2. eliciting effect 
On day 0，2x10^  EAT cells in 0.2ml PBS was inoculated into ICR mice (10 
per group). On day 7，2mg of sample was injected iv into mice. After 90min of 
injection, 3 mice were bled to collect the serum. Ascitic fluid was collected 
simultaneously. Both the serum and ascitic fluid were heat inactivated at 56°C for 
30min, and stored at -70。C for TNF activity determination. On day 9，EAT cells 
were collected from the remaining mice and counted with a hemocytometer. LPS 
(25/xg per mouse) was injected intravenously as positive control. 
Chapter 3 33 
Chapter 3 Preparation of sample 
3.1 Alcohol precipitation of Bupleuri radix 
Bupleuri radix was brown in colour. After cutting into pieces, 200g of 
Bupleuri radix was suspended in 2 litre of distilled water and heated at 90°C for 
4h. Insoluble substances were removed by centrifugation. Crude substances were 
obtained by alcohol precipitation. The product was designated as BR crude. BR 
crude extract was powder-liked and brown in colour. The percentage yield of BR 
crude was 3.4%. 
BR crude was then further fractionated by stepwise alcohol precipitation. 
Five fractions were separated and designated as BRO, BRI, BRII, BRIII, and 
BRIV. BRO to BRIII were the precipitate of each step of precipitation. The 
supernatant, BRIV, obtained at the last step of precipitation was evapourated to 
remove alcohol content. Only slightly water-soluble substances were left in the 
supernatant and lyophilized to become BRIV. The percentage yield of BRO, BRI, 
BRII, BRIII, and BRIV were 42.6%, 23.9%, 9.5%, 3.9%, and 7.0% respectively 
(Table 3.1). 
The stepwise alcohol precipitation was used to isolate substances based on 
the molecular size. With hot-water extraction and alcohol precipitation, the water-
soluble substances were mainly carbohydrates. Those precipitated at the first step 
with alcohol concentration of 47.5% were the most polar and having largest 
molecular size. BRO mainly contained polysaccharides with largest molecular size. 
By adding equal volume of 95% alcohol, the concentration of alcohol increased 
stepwisely from 71.3%, 83.2%, to 89.1%. BRI, BRII, and BRIII were obtained 
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with decreasing molecular weight. BRIV contained mainly non-polar or slightly 
water-soluble substances with smallest molecular size. 
By the use of phenol-sulphuric acid method, BR crude, and BRO to BRIII 
were found to contain quite high content of carbohydrate, ranging 30-40% (Table 
3.2). BRO and BRI had very low protein contents (about 1-10%), whereas, BRII 
and BRIII had high protein contents, about 30%. Thus, BRI being studied mainly 
contained polysaccharides. Panax quinquefolium fraction I (PQI), in the same 
isolation procedure as Bupleuri radix, contained mainly polysaccharide, with 
41.6 ±3.0% carbohydrate and 0.3 ±0.6% protein. 
、 
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Table 3.1 Percentage yield of Bupleuri radix fractions 
fractions yield (%) ^  
BRO 42.6 ± 0.74 
BRI 23.9 土 0.23 
BRII 9.5 ± 0.61 
BRIII 3.9 土 0.61 
BRIV 7.0 ± 0.00 
a Percentage yield from BR crude. 
• •！ 
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Table 3.2 Carbohydrate and protein composition in Bupleuri radix and 
Panax quinquefolium 
carbohydrate (%) ^ protein (%) b 
Panax quinquefolium (PQI) 41.6 土 3.01 0.3 土 0.57 
Bupleuri radix (BR) 32.3 ± 4.15 8.7 ± 2.02 
BRO 21.6 ± 4/71 10.5 ± 0.50 
BRI 35.0 ± 2.66 1.8 ± 2.47 
BRII 37.4 土 4.84 28.8 ± 5.30 
BRIII 41.7 土 3.37 30.3 ± 1.77 
a Carbohydrate content was determined by the phenol-sulphuric acid method, 
b Protein content was determined by the Lowry method. 
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32 Endogenous TNF production by BR fractions 
5mg of BR crude, BRO, BRI, BRII, or BRIV were injected iv into ICR 
mice. After 2h of iv injection, mice were bled to collect serum for TNF activity 
determination. 25jLtg of LPS was injected as a positive control. Blood was drawn 
after 2h of LPS injection. 
TNF activity in serum treated with LPS was 67 ±16 units/ml. For those 
treated with BR fractions, there was no detectable TNF activity present in the 
serum. 
The endogenous TNF production by PQI was also tested. ICR mice were 
treated with 5mg of PQI in 0.2ml of PBS by iv injection. After 2h, mice were bled 
to collect serum. There was no detectable TNF activity present in the serum. 
However, it was believed that the molecular size of fraction I was about 
lO-lOOkD. Evidence reported that those polysaccharide extracted from bacterial 
preparation or higher plant had the molecular size of about lOOkD. These kind 
of polysaccharide had the ability to induce endogenous TNF production 
(Sakagami et al, 1992). Fraction I of Pseudostellaria heterophylla (PHI), isolated 
in the same procedure as Bupleuri radix and Panax quinquefolium, was found to 
have the highest mitogenic activity as well as TNF eliciting activity among the 
other fractions (Wong, 1993). Kok (1993) found that fraction I oi Bupleuri radix 
hot water extract also had the highest mitogenic activity among the other 
subfractions. Thus, fraction I of Bupleuri radix: and Panax quinquefolium were 
further purified and studied. 
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Chapter 4 Purification of BRI 
4.1 Gel filtration chromatography of BRI 
BRI (800mg) was dissolved in distilled H2O, at a concentration of 
lOOmg/ml, and applied onto a column (5x89cm) of Sephadex G-100. The column 
was eluted with degassed ditilled H2O. Fractions of 10ml were collected and 
analyzed by phenol-sulphuric acid method. Two peaks were obtained (Fig 4.1). 
BRIA was obtained from tubes 59-80, BRIB was obtained from tubes 105 to 155. 
After concentration and lyophilization, fraction A and B were designated as BRIA 
and BRIB respectively. BRIA was white in colour and woolly-liked, whereas 
BRIB was brown and woolly-liked. The percentage yields of BRIA and BRIB 
were 18.4% and 66.7% of BRI, respectively (Table 4.1). 
By the phenol-sulphuric acid method, both the BRIA and BRIB were 
found to be rich in carbohydrate, but low content of protein, about 2% (Table 
4.2). BRIA had higher carbohydrate content (74%) than BRIB (44%). In contrast, 
with carbazole assay, BRIB contained more uronic acid (33%) than BRIA 
(13.2%). 
Since BRIA and BRIB were obtained from gel filtration chromatography, 
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Table 4.1 Percentage yields of BRI subfractions 
fractions yield (%) ^  
BRIA 18.4 土 1.15 
BRIB 66.7 ± 2.37 
a Percentage yield from BRI. 
> 
- Chapter 4 41 
Table 4.2 Carbohydrate, protein, and uronic acid composition in Bupleuri 
radix subfractions 
carbohydrate (%) ^ protein (%) ^ uronic acid (%)。 
BRIA 74.0 土 1.3 2.0 ± 2.8 13.2 土 0.7 
BRIB 44.0 ± 1.7 2.5 ± 3.5 33.0 土 0.2 
a Carbohydrate content was determined by the phenol-sulphuric acid method, 
b Protein content was determined by the Lowry method. 
c Uronic acid was determined by the carbazole assay. 
> 
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Figure 4.2 Selectivity curve of Sephadex G-100. Dextran was run on a 5x89cm 
column of Sephadex G-100. The K^^  values for dextran with molecular weight of 
66700，38900，9500, and 5000 were 0.06, 0.096，0.547, and 0.824 respectively. 
• . 
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Dextran standard with average molecular size of 66700Da, 38900Da, 
9500Da, and 5000Da were dissolved in distilled H2O and run on a column 
(5x89cm) of Sephadex G-lOO separately to obtain a calibration curve. The 
partition coefficient (KJ) of carbohydrate having different molecular size was 
calculated by the following equation : 
Kav = (Ve-V,)/(V,-VJ 
where V^ is the elution volume, V。is the void volume determined by blue 
dextran, and Vj is the total volume of packed bed. A calibration curve for 
Sephadex G-lOO was obtained. The K^^ values for 66700Da, 38900Da, 9500Da, 
and SOOODa were 0.060，0.096，0.547, and 0.824 respectively (Fig 4.2). 
The K v^ values for BRIA and BRIB were 0.033 and 0.366 respectively. 
With respect to the calibration curve, BRIA was having a molecular size of about 
60KD, and BRIB had an estimated molecular size of 20-30kD. 
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4.2 Anion exchange chromatography 
BRIA (150mg) was dissolved in lOmM NaCl phosphate buffer and run on 
a 2xl5cm column of DEAE-Sephadex (Fig 4.3). Fraction A eluted with lOmM 
NaCl phosphate buffer was obtained from tubes 1 to 10. This fraction contained 
mainly neutral and low charge polysaccharides. Fraction B was obtained from 
tubes 21 to 35. After dialysis and lyophilization, fraction A which appeared as 
white and woolly-liked was designated as BRIAa. The negatively charged portion, 
fraction B, was slightly brown in colour and woolly-liked, and was designated as 
BRIAb. The percentage yields were 15.1% for BRIAa, and 76.7% for BRIAb 
(Table 4.3). 
BRIB (150mg) was also run on a 2x 15cm column of DEAE-Sephadex (Fig 
4.4). The first fraction eluted with lOmM NaCl phosphate buffer was obtained 
from tubes 1 to 14. The column was then eluted with SOOmM NaCl phosphate 
buffer, but the brown pigment still bound on the DEAE-Sephadex. The ionic 
strength of SOOmM NaCl phosphate buffer was not strong enough to elute all the 
negatively charged substances of BRIB. IM NaCl phosphate buffer was then 
applied to elute negatively charged portion of BRIB. Most of the brown pigment 
was eluted out, but there was still a little amount of pigment remained on the 
DEAE-Sephadex. However, with phenol-sulphuric acid determination, the 
pigment remained on the column had no detectable carbohydrate content. 
Carbohydrates with negatively charged was rich in the fraction already eluted with 
SOOmM. Thus, lOmM and SOOmM NaCl phosphate buffer were chosen for the 
anion exchange chromatography of BRIB. After dialysis and lyophilization, the 
fraction eluted with lOmM NaCl phosphate buffer was white in colour and woolly-
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liked, and was designated as BRIBa. The negatively charged portion of BRIB was 
obtained as brown powder, and was designated as BRIBb. The percentage yields 
of BRIBa and BRIBb were 17.4% and 26.7% respectively (Table 4.3). 
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Figure 4.3 Anion exchange chromatography of BRIA. BRIA was run on a 
column of DEAE-Sephadex. BRIAa was obtained from fractions eluted with 
lOmM NaCl phosphate buffer, BRIAb was eluted with 500mM NaCl phosphate 
buffer. 
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Figure 4.4 Anion exchange chromatography of BRIB. BRIB was run on a 
column of DEAE-Sephadex. BRIBa was obtained from fractions eluted with 
lOmM NaCl phosphate buffer, BRIBb was eluted with IM NaCl phosphate buffer. 
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Table 4.3 Percentage yields of BRIA and BRIB subfractions 
fractions yield (%) 
BRIAa 15.1 土 6.38 ^ 
BRIAb 76.7 土 6.85 ^ 
BRIBa 17.4 土 2.42 ^ 
BRIBb 26.7 土 2.21 b 
a Percentage yield from BRIA. 
b Percentage yield from BRIB. 
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Carbohydrate and uronic acid contents in these Bupleuri radix, subfractions 
were determined by phenol-sulphuric acid method and carbazole assay (Table 
4.4). BRIAb, IBa, and IBb were rich in carbohydrate 50-60%. The uronic acid 
content in these BR subfractions were high also. Among these subfractions, the 
negatively charged portion of BRIB, BRIBb, had the highest uronic acid content 
of 38%. BRIAa had the lowest uronic acid content with 7.5%. The protein 
content in these BRIA and BRIB fractions were very low, only 2-3%, while 
BRIBb had 10% of protein content. 
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Table 4.4 Carbohydrate, protein, and uronic acid composition in BRI 
subfractions 
carbohydrate (%) ^ protein (%) ^ uronic acid (%)。 
BRIAa 37.8 土 0.9 3.3 ± 1.8 7.5 土 0.5 
BRIAb 59.1 ± 1.9 3.3 土 0.4 19.8 ± 1.5 
BRIBa 58.3 ± 1.2 2.8 ± 0.2 24.4 土 1.6 
BRIBb 47.8 ± 2.3 9.9 ± 1.1 38.0 ± 1.4 
a Carbohydrate content was determined by the phenol-sulphuric acid method, 
b Protein content was determined by the Lowry method, 
c Uronic acid was determined by the carbazole assay. 
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Chapter 5 Purification of PQI 
5.1 Gel filtration chromatography of PQI 
PQI (800mg) was dissolved in distilled H / ) and run on a 5x89cm column 
of Sephadex G-lOO (Fig 5.1). The column was eluted with degassed distilled H2O. 
Fractions of 10ml were collected and analyzed by phenol-sulphuric acid method. 
Fraction A was obtained from tubes 58 to 80，fraction B from tubes 81 to 133, 
fraction C from tubes 134 to 181. After concentration and lyophilization, fraction 
A and fraction B were obtained as white and wooly-liked, designated as PQIA 
and PQIB respectively. PQIC was obtained from fraction C. It was slightly brown-
yellow powder. The percentage yields of PQIA, IB, and IC were 19.5%, 18.6%, 
and 44% respectively (Table 5.1). 
With the use of phenol-sulphuric acid method, PQIA was determined to 
have the highest carbohydrate content (58.8%), and PQIC had the least (28.5%) 
(Table 5.2). For the determination of uronic acid, PQIA was found to have the 
least uronic acid content (37.2%) by carbazole method, while PQIC being the 
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Table 5.1 Percentage yields of PQI subfractions 
fractions yield (%) ^  
PQIA 19.47 土 3.33 
PQIB 18.57 土 1.92 
PQIC 44.03 ± 0.98 
a Percentage yield from PQI. 
- Chapter 4 54 
Table 5.2 Carbohydrate, protein, and uronic acid composition in PQI 
subfractions 
carbohydrate (%) ® protein (%) ^ uronic acid (%)。 
PQIA 58.8 土 2.1 0.9 ± 0.6 37.2 土 0.1 
PQIB 40.2 土 3.9 3.5 ± 0.8 64.1 ± 1.7 
PQIC 28.5 土 5.2 3.7 土 1.0 81.5 ± 3.2 
a Carbohydrate content was determined by the phenol-sulphuric acid method, 
b Protein content was determined by the Lowry method, 
c Uronic acid content was determined by the carbazole assay. 
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The molecular size of PQI fractions were estimated with respect to the 
calibration curve of dextran standard. According to the equation, 
Kav = (Ve-Vo)/(Vt-Vo) 
the K v^ values for PQIA, IB, and IC were 0.049，0.366, and 0.853 respectively. 
PQIA had the estimated molecular size of 60kD, PQIB was 20-30kD, and PQIC 
was the smallest one with 4kD. 
5.2 Anion exchange chromatography 
PQIA (150mg) was dissolved in 1.5ml of lOmM NaCl phosphate buffer and 
run on a 2xl5cm column of DEAE-Sephadex (Fig 5.2). Fractions of 7ml was 
collected and analyzed by phenol-sulphuric acid method. The negatively charged 
portion of PQIA was eluted with 500mM NaCl phosphate buffer. When the 
absorbance at 490iim (carbohydrate content) declined to undetectable level, IM 
NaCl phosphate buffer was applied to elute the column. However, the eluates did 
not show any carbohydrate content. Thus, SOOmM NaCl phosphate buffer was 
strong enough to elute the negatively charged substances of PQIA. After dialysis 
and lyophilization, PQIAa (neutral or low charged) was obtained from the 
fraction eluted by lOmM NaCl phosphate buffer, while PQIAb (negatively 
charged) was obtained from the fraction eluted by SOOmM NaCl phosphate buffer. 
Both the PQIAa and PQIAb were white and woolly-liked, with the percentage 
yield of 17.6% and 83.1% respectively (Table 5.3). 
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Figure 5.2 Anion exchange chromatography of PQIA. PQIA was run on a 
column of DEAE-sephadex. PQIAa was obtained from fractions eluted with 
lOmM NaCl phosphate buffer, PQIAb was obtained from fractions eluted with 
500mM NaCl phosphate buffer. 
- Chapter 4 57 
Table 5.3 Percentage yields of PQIA, IB, and IC subfractions 
fractions yield (%) 
PQIAa 17.60 土 3.54 “ 
PQIAb 83.10 ± 4.24 ^ 
PQIBa 27.50 土 6.50 & 
PQIBb 56.10 土 8.49 b 
PQICa 24.60 土 0.85 ^ 
PQICb 65.75 ± 3.89。 
Percentage yield from ^ PQIA, ‘ PQIB,' PQIC. 
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PQIB and PQIC were also fractionated by anion exchange chromatography 
on a 2xl5cm column of DEAE-Sephadex (Fig 5.3 & 5.4). The neutral and 
positively charged carbohydrates were eluted with lOmM NaCl phosphate buffer. 
500mM NaCl phosphate buffer was strong enough to elute the negatively charged 
carbohydrates from PQIB and PQIC. Although IM NaCl phosphate buffer was 
applied following 500mM NaCl phosphate buffer, the eluates did not contain 
carbohydrate, The fractions collected were dialyzed against distilled water and 
lyophilized. Both the PQIBa (neutral and low charged portion) and PQIBb 
(negatively charged portion) were obtained as white and woolly-liked, with the 
percentage yields of 27.5% and 56.1% respectively (Table 5.3). PQICa was the 
neutral and low charged carbohydrates, and obtained as white and woolly-liked. 
PQICb was negatively charged carbohydrates, and obtained as light yellow brown 
powder. The percentage yield of PQICa was 24.6%, and 65.8% for PQICb. 
By phenol-sulphuric acid method, PQIAb had higher carbohydrate content 
than PQIAa (Table 5.4). Both the PQIBa and PQICa contained very high content 
of carbohydrate, with 83.5% and 63.7% respectively. With carbazole assay, PQIBb 
contained 81.9% uronic acid，and PQIcb contained 99.6% uronic acid. With 
respect to the highest uronic acid content of PQIC, the negatively charged 
substances of PQIC were mainly uronic acid. PQIAb only contained 36% of 
uronic acid. 
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Figure 5.3 Anion exchange chromatography of PQIB. PQIB was run on a 
column of DEAE-sephadex. PQIBa was obtained from fractions eluted with 
lOmM NaCl phosphate buffer, PQIBb was obtained from fractions eluted with 
SOOmM NaCl phosphate buffer. 
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Figure 5.4 Anion exchange chromatography of PQIC. PQIC was run on a 
column of DEAE-sephadex. PQICa was obtained from fractions eluted with 
lOmM NaCl phosphate buffer, PQICb was obtained from fractions eluted with 
SOOmM NaCl phosphate buffer. 
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Table 5.4 Carbohydrate, protein, and uronic acid composition in PQI 
subfractions 
carbohydrate protein (%)匕 uronic acid (%)。 
lAa 37.5 土 2.3 1.3 ± 0.4 7.6 ± 0.00 
lAb 51.7 ± 0.6 1.1 土 0.2 36.0 ± 1.0 
IBa 83.5 土 0.5 0 16.5 ± 0.7 
IBb 32.4 土 0.1 1.5 土 0.2 81.9 土 1.7 
ICa 63.7 土 1.3 2.0 土 0.8 24.7 土 0.9 
ICb 32.2 土 1.4 2.8 土 1.0 99.6 土 4.6 
a Carbohydrate content was determined by the phenol-sulphuric acid method, 
b Protein content was determined by the Lowry method. 
c Uronic acid content was determined by the carbazole assay. 
、 、 
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Chapter 6 Capacity of BR and PQ as eliciting 
agent for endogenous TNF production 
% 
6.1 Time course of endogenous TNF production by BRI subfractions 
BRIA or BRIB (2mg) in 0.2ml of PBS was injected ivinto ICR mice (3 per 
group). The control group was maintained by injecting PBS intravenously. LPS 
(25/xg per mouse) was injected as the positive control. After 30min to 6h, mice 
were bled to collect serum. 
Those mice received LPS, there was detectable TNF activity present in the 
serum just after 30min of injection (Fig 6.1). The maximum TNF titre was 
1378+371 units/ml peaked at 60-90min. Since the circulating half life of murine 
TNF was only 6-7min, TNF titre declined rapidly and became undetectable after 
ft 
4h of injection. 
BRIA treated mice also responded to have a TNF titre peak of 200 
units/ml after Ih of iv injection. TNF titre then declined to undetectable level for 
a further 30min (Fig 6.2). 
BRIB treated mice gave a higher TNF activity in serum than that of BRIA 
(Fig 6.2).TNF activity was detectable after SOmin of injection and reached a peak 
of 3162 units/ml at Ih. Then the activity declined to undetectable level at 4h. 
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Figure 6.1 Time course of TNF release from mice treated with LPS. LPS 
(25iLtg) was injected iv into mice (3 in group). After indicated period, blood was 
drawn to collect serum. Serum TNF activity was determined by in vitro L929 
assay. 
TNS, TNF containing serum. 
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Figure 6.2 Time course of TNF release from mice treated with BRI 
subfractions. 2mg of BRIA (•) or BRIB (•) injected iv into mice (3 in group). 
After indicated period, blood was drawn to collected serum. Serum TNF activity 
was determined by in vitro L929 assay. 
TNS, TNF containing serum. 
Chapter 6 65 
6.2 Time course of endogenous TNF production by PQI subfractions 
PQIA, IB, or IC (2mg) was dissolved in PBS at a concentration of 
lOmg/ml. ICR mice (3 per group) recieved 2mg of samples by iv injection. After 
30min to 6h, mice were anaesthetized to collect blood. After coagulation at room 
temperature, serum was separated immediately by centrifugation. TNF activity in 
serum was determined by in vitro L929 assay. 
All the PQIA, IB, and IC could mediate TNF release in serum after Ih of 
injection (Fig 6.3). PQIC mediated the highest TNF activity of 648 ± 147 units/ml 
at Ih. TNF activity then declined rapidly to undetectable level for a further 3h. 
PQIA and PQIB only mediated TNF activity of about 250 units/ml at Ih of 
injection. TNF activity in serum then declined to undetectable level within a 
further Ih. 
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Figure 6.3 Time course of TNF release from mice treated with PQI 
subfractions. 2mg of PQIA(-), PQIB(^), or PQIC(-) were injected iv into mice 
(3 in group). After indicated period, blood was drawn to collected serum. Serum 
TNF activity was determined by in vitro L929 assay. 
TNS, TNF containing serum. 
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6.3 BRI subtractions as eliciting agent 
Each ICR mouse (3 per group) was treated with 100/xg to 2mg of BRIA 
or BRIB subfractions by iv injection. After Ih, blood was drawn to collect serum. 
» 
TNF activities present in the serum were determined by murine TNF-a ELISA 
kit (Genzyme Co.). The sensitivity of this kit is limited to lOOpg/ml. 
Both the BRIBa and ffib were able to trigger TNF release in serum in a 
dose-dependent manner. Significant TNF activities were detected when the mice 
were treated with 500/xg of BRIBa or BRIBb. When the dose increased upto 2mg, 
TNF activity triggered by BRIBb increased larger than BRIBa. At the dose of 
2mg per mouse, BRIBb triggered significant higher TNF activity (1.8 土0.08ng/ml) 
than BRIBa (0.87土0.05ng/ml) (Fig 6.4). 
Correspond to the time course study of endogenous TNF production, 
BRIA only mediated 200 units/ml of TNF after Ih of iv injection. When various 
dose ofBRIAa and BRIAb were injected into mice, both the BRIAa and BRIAb 
(at dose ranging 100/xg to 2mg per mouse) could not mediate endogenous TNF 
release. Only when mice recieved 2mg of BRIAb, there was only 0.136 ng/ml of 
TNF release into the serum (Fig 6.4). 
ft 
•- ' 、 、’ 
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Figure 6.4 Dose effect of BRI subfractions on endogenous TNF release. 2mg 
of BRIAa( •), BRIAb(o), BRIBa (•), or BRIBb( v) were injected iv into mice (3 
in group). After 60 min，blood was drawn to collected serum. Serum TNF activity 
was determined by murine TNF-a ELISA kit. 
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6.4 PQI subfractions as eliciting agents 
PQIAa, lAb, ICa, or ICb were dissolved in PBS at a dose ranging lOO/xg 
to 2mg per mouse. The samples were injected iv into ICR mice (3 per group). 
After Ih, mice were bled to collect serum. TNF activity present in serum was 
determined by murine TNF-a ELISA kit. 
Both the PQICa and PQICb were able to trigger detectable TNF release 
into mice at a dose of 500/ig per mouse. The potencies of PQICa and PQICb in 
triggering TNF release were similar. At a dose of 2mg per mouse, TNF activity 
mediated by PQICa and ICb were 1.86 ±0.04 ng/ml and 1.78 ng/ml (Fig 6.5). 
Both of them responded in a dose-dependent curve. As the dosage increased, 
TNF activities triggered by PQICa or PQICb increased in a similar manner. 
PQIAa and PQIAb were studied if they could mediate endogenous TNF 
release in dose-dependent manner. Both of them could only induce a small 
amount of TNF release, even at a dosage of 2mg sample/mouse. TNF activity 
detected in serum was only 0.136 ng/ml for PQIAa and 0.123 ng/ml for PQIAb 
(Fig 6.5). 
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Figttre 6.5 Dose effect of PQI subfractions on endogenous TNF release. 2mg 
of PQIAa( •), PQIAb(o), PQICa (•)，or PlCb(v) were injected iv into mice (3 in 
group). After 60 min, blood was drawn to collected serum. Serum TNF activity 
was determined by murine TNF-a ELISA kit. 
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Chapter 7 Are BR and PQ priming agents in 
endogenous TNF production ？ 
Sakagami et al (1992) reported that natural products isolated from bacteria 
having priming activity on endogenous TNF production had a large molecular size 
ranging 50-200kD or much larger. Their results suggested that the priming activity 
of these bacterial preparations might depend on their molecular size. 
In order to understand the relationship between molecular size and 
priming activity, the priming activity of high molecular weight components was 
studied. BRIA and PQIA had an estimated molecular size of 60kD. Both of them 
were rich in negatively charged polysaccharides, BRIA had 76.7%, and PQIA had 
83.1%. Thus, BRIAb and PQIAb were chosen to study the priming activity on 
TNF production. 
7.1 Priming by intraperitoneal route 
BRIAb or PQIAb (2mg in 0.5ml of PBS) was injected ip into ICR mice (3 
per group). After 2 to 48h, 25/xg of LPS in 0.2ml of PBS was injected iv. After a 
further 90min, mice were bled to collect serum for TNF activity determination by 
L929 bioassay. Mice received PBS ip, followed by 25iJLg of LPS iv was used as LPS 
control. The negative control group was performed by injecting PBS ip, followed 
by PBS iv. 
TNF activity in serum of mice treated with LPS alone was 1173 ±122 
units/ml. When mice were primed with PBS for 2 to 48h, and then challenged 
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with 25/xg of LPS, the TNF activity in serum was 1379± 135 units/ml. PBS was 
unable to prime peritoneal macrophages to amplify LPS-induced TNF release. 
When mice were primed with BRIAb intraperitoneally for 2 to 48h, 
followed by LPS challenge, there was no significant increase or decrease in serum 
TNF activity, ranging 1400 to 1600 units/ml. BRIAb seemed unable to act as a 
priming agent to amplify the LPS-induced TNF release in this 48h period (Fig 
7.1). 
In contrast, PQIAb suppressed the LPS-induced TNF release. When mouse 
intraperitoneal macrophages were treated with PQIAb for 2 to 4h, there was no 
detectable serum TNF activity after LPS injection. Serum TNF activity was then 
slightly increased. However, it was much lower than that induced by LPS alone. 
i 
When pretreated with PQIAb for 48h, there was only 100 units/ml of serum TNF 
activity. Pretreatment with PQIAb intraperitoneally could suppress LPS-induced 
endogenous TNF production. 
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Figure 7.1 Effect of intraperitoneal pretreatment of samples on endogenous 
TNF release. 2mg ofBRIAb(«), PQIAb(v), or PBS(n) were injected ip into mice 
(3 in group). After indicated period of treatment, 25iig of LPS was injected iv. 
After a further 90min, blood was drawn to collected serum. Serum TNF activity 
was determined by in vitro L929 assay. 
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7.2 Priming by intravenous route 
BRIAb or PQIAb (2mg in 0.2ml of PBS) was injected iv into ICR mice (3 
per group). After 2 to 48h, mice were challenged with 25fig LPS iv. Serum was 
collected after 90min of LPS injection. LPS with PBS iv pretreatment could 
trigger 1413 units/ml of serum TNF activity。 
When mice pretreated with BRIAb intravenously for 2h, there was 
undetectable serum TNF activity after LPS challenge, the activity then increased 
slightly to 1413 units/ml for mice pretreated for 6h (Fig 7.2). For further 1 to 2 
days，serum TNF activity did not changed, remained to be 1413 units/ml. 
Pretreatment of mice with PQIAb with intravenous route totally inhibited 
LPS-induced TNF release. Even when mice pretreated for 48h, follwed by LPS 
injection, there was no detectable serum TNF activity. 
Both of the BRIAb and PQIAb failed to amplify the LPS-induced TNF 
release, while PQIAb even suppressed the LPS-induced TNF release. The 
suppressive effect was greater by intravenous administration than intraperitoneal 
administration. This might be due to : (1) blockage of monocyte/macrophage 
surface receptor for LPS-LPS binding protein complex by BRIAb and PQIAb; (2) 
desensitization of monocytes/macrophages that made the cells unable to respond 
to LPS challenge. 
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Figure 7»2 Effect of intravenous pretreatment of samples on endogenous TNF 
release. 2mg of BRIAb(o), PQIAb(v), or PBS(_) were injected iv into mice (3 in 
group). After indicated period of treatment, 25/xg of LPS was injected iv. After 
a further 90inin, blood was drawn to collected serum. Serum TNF activity was 
determined by in vitro L929 assay. 
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LPS requires serum lipopolysaccharide-binding protein (LBP) to act as an 
opsonin. The complex of LPS-LBP could bind to CD 14 on monocyte/macrophage, 
leading to macrophage activation. LBP itself binds to lipid A of LPS with high 
affinity (K^,� lO'^M). BRIAb and PQIAb were carbohydrate-riched polymer 
(60kD). They might block the CD 14 surface glycoprotein by non-specific 
carbohydrate recognition. Since LPS-LBP complexes were 1000-fold more active 
than LPS alone in TNF induction (Gallay et al, 1993)，the blockage of CD14 
would result in a dramatic decrease in LPS-induced TNF release. 
Zuckerman et al (1989) reported that pretreatment of macrophages with 
low amount of LPS would make macrophages became LPS-refractory (or 
macrophage desensitization, or LPS tolerance). Therefore, the cell became 
unresponsiveness to second LPS-stimulus. There was a reduction in TNF release 
in LPS-refractory macrophages. The in vivo LPS-induced desensitization was 
reversible and was dependent on the in vivo LPS concentration. Their result 
reported that macrophages from mice injected with O.ljitg of LPS were not 
refractory and were able to respond to a second LPS stimulus. Only when 
macrophages from mice pretreated with l^g of LPS were refractory, and required 
2 day to become responsive to a second LPS stimulus. If mice treated with lO/ig 
of LPS，the refractory macrophages required 6 days to become responsive to a 
second LPS stimulus. 
Both of the BRIAb and PQIAb might mediate similar effect as LPS in 
monocyte/macrophage desensitization. PQIAb itself at 2mg dosage could mediate 
TNF release with 0.123 ng/ml by intravenous administration Fig 6.5). Once blood 
monocytes had been activated by PQIAb with TNF induction, monocytes might 
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not respond to a second stimulus, such as LPS. Monocytes were desensitized and 
failed to retain its responsiveness to LPS, even after 48h of pretreatment. 
BRIAb itself (at 2mg dosage) were able to induce TNF release by 
intravenous administration (0.136 ng/ml, Fig 6.4). Although BRIAb induced 
similar amount of serum TNF activity as PQIAb, the desensitization of 
monocyte/macrophage by BRIAb was not as strong as PQIAb. After iv 
pretreatment with BRIAb for 6h, the mice became already responsive to LPS 
challenge. 
With iv or ip administration of sample, the effect of sample might be 
different. When mice received sample treatment by iv administration, blood 
monocytes were pretreated in this manner, and TNF would be released. LPS was 
then administered by iv injection. LPS bound to blood monocytes in the presence 
of serum LBP and would probably trigger the release of TNF. However, since the 
monocytes had already been desensitized by the sample, release of TNF by a 
second stimulus might be impossible. Serum TNF being detected might be mainly 
came from blood monocytes, thus there was no detectable TNF activity. 
In contrast, ip administration of sample only acted on intraperitoneal 
macrophages. Mice were then challenged by iv injection of LPS, which combined 
% 
with LBP to become LPS-LBP complex. Mouse LBP molecule is large, with 
molecular weight of 61kD (Galley et al，1993). As a result, LPS-LBP complexes 
were unable to pass through vascular membrane into peritoneal cavity to activate 
peritoneal macrophage. 
The data suggested that intraperitoneal administration of BRIAb might not 
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desensitize blood monocytes to become unresponsive to LPS, or did not amplify 
LPS-induced TNF release. With intraperitoneal pretreatment of PQIAb, the LPS-
induced TNF release was suppressed. However, the reason for its suppressive 
effect is unknown. 
. ‘ . ， . . . - - 一 . ‘ ‘ 
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Chapter 8 Removal of LPS by acetic acid treatment 
The KDO-lipid A linkage of LPS was acid labile, thus this linkage could 
be broken by acid hydrolysis. When LPS was treated with 1% acetic acid (v/v) at 
100®C for 90min, lipid A released out and formed precipitate, leaving the core 
and O-antigen in the solution (Ha et al, 1985). After centrifugation, lipid A was 
removed. 
LPS with acetic acid treatment was injected iv into mice. After 90min, 
blood was drawn to determine serum TNF activity. The result showed that there 
was no detectable serum TNF activity. Acetic acid treatment was successful to 
abolish the activity of LPS in TNF induction. It was because lipid A portion 
possesses most of the biological activities of LPS in macrophage activation, 
resulting in TNF production. Thus, removal of lipid A was successful to abolish 
TNF production completely. 
BRIB, BRIBb, PQIC, and PQICb were found to be able to trigger 
endogenous TNF production. The question came out whether TNF production 
was mediated by LPS contamination. These samples were then treated with acetic 
acid to remove lipid A. 
After acetic acid treatment, the percentage yields for BRIB and BRIBb 
were 58% and 71% respectively, whereas 49% and 64% for PQIC and PQICb 
respectively. Samples (lOmg) were treated with acetic acid, treated samples were 
redissolved in 1ml of PBS to give a concentation (lOmg/ml) equal to untreated 
sample. Sample solution (0.2ml) was injected iv into mice. After 60min, blood was 
drawn to determine serum TNF activity. As compared to 2mg of untreated BRIB 
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and BRIBb, there was decrease in serum TNF activity after acetic acid treatment. 
For BRIB, serum TNF activity decreased from 3162 units/ml to 89 units/ml 
(Table 8.1), while BRffib only mediated 141 units/ml (-0.143ng/ml) of TNF 
activity. Untreated BRIBb could mediate 1.8土O.lng/ml of TNF (Fig 6.4). When 
PQIC and PQICb were treated with acetic acid, endogenous TNF production was 
abolished. These data suggested that the samples might be contaminated with 
LPS. After removal of lipid A by acetic acid treatment, most of the activity 
mediating TNF induction was abolished. The ability in mediating TNF induction 
by these untreated samples might come from LPS mainly. However, Kok (1993) 
reported that the mitogenic activity mediated by fraction I of Bupleuri radix (BRI) 
did not change significantly with polymycin B coculture. Polymycin B was 
commonly used to abolish LPS activity in in vitro assay. 
% 
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Table 8.1 Effect of acetic acid treated sample in endogenous TNF 
production 
TNF titer (units/ml) 
without acetic acid with acetic acid 
treatment treatment 
BRIB 3162 89 
BRIBb 3981 141 
PQIC 794 ND 
PQICb 1995 ND 
BRIB, BRIBb, PQIC, or PQICb (lOmg) were treated in 1% acetic acid at 100°C 
for 90min. Precipitate was removed by centrifugation. Sample solution mixture 
was dialyzed against distilled water and lyophilized. Acetic acid treated samples 
were redissolved in 1ml of PBS. 0.2ml of sample solution was injected iv into mice 
(3 per group). After 60min, blood was drawn to collect serum. Serum TNF activity 
was determined by in vitro L929 assay. One unit of TNF activity was defined as 
the amount of TNF producing 50% of cytotoxicity. 
ND, undetectable. 
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The carbohydrate and uronic acid content in these acetic acid treated 
samples were determined (Table 8.2). With phenol-sulphuric acid method, there 
was a significant decrease in carbohydrate after acid treatment. For BRIB, 
carbohydrate content decreased from 44.0土 1.7% to 25.5土3.2%，while significant 
change of carbohydrate content from 47.8±2.3% to 32.7±1.3% was observed in 
BRIBb after acid treatment. Decrease in carbohydrate content was also observed 
in sample PQIC and PQICb, there was 48% decrease. In contrast, there was no 
significant change of carbohydrate content in PQIC after acetic acid treatment. 
Uronic acid content was also determined by carbazole assay. The uronic 
acid content in BRIB was decreased from 33.0 ±0.2% to 13.4 ±0.7% after acetic 
acid treatment, while the uronic acid content in BRIBb was changed from 
38 ±1.4% to 23.4 ±0.8% (Table 8.2). Both the PQIC and PQICb were uronic acid-
riched (contained 80 to 90%), but with acetic acid treatment, there was a 11% 
(PQIC) and 37% (PQICb) decrease in uronic acid content. 
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Table 8.2 Carbohydrate and uronic acid content in acetic acid treated 
samples 
without acetic acid treatment with acetic acid treatment 
carbohydrate % uronic acid % carbohydrate % uronic acid % 
BRIB 44.0 土 1.7 33.0 土 0.2 土 3.2 *13.4 土 0.7 
BRIBb 47.8 ± 2.3 38.0 ± 1.4 *32.7 ± 1.3 *23.4 ± 0.8 
PQIC 28.5 土 5.2 81.5 土 3.2 22.6 土 4.4 *72.2 土 2.9 
PQICb 32.2 ± 1.4 99.6 ± 4.6 *152 ± 3.3 "62.8 ± 1.9 
lOmg of BRIB, BRIBb, PQIC, or PQICb were treated in 1% of acetic acid at 
100。C for 90inin. Precipitate was removed by centrifugation. The solution was 
then dialyzed against distilled water and lyophilized. Acetic acid treated sample 
was redissolved in 1ml of PBS. Carbohydrate and uronic acid content in this 
acetic acid treated sample were determined. 
本 p < 0.05 
) 
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The decrease in carbohydrate and uronic acid content suggested that the 
carbohydrate present in these sample might be acid labile. With acid hydrolysis, 
the acid labile carbohydrate was hydrolyzed to smaller molecules. The dialyzing 
tube being used had a molecular size cutoff value of 1200, these small molecules 
might be dialyzed out. As a result, there was a decrease in yield, carbohydrate and 
uronic acid content after acetic acid treatment. Thus, one could not conclude that 
the decrease in TNF production was due to LPS removal or decrease in 
carbohydrate or uronic acid content. Further experiments may be needed to 
confirm this. 
This experiment demonstrated that acetic acid treatment was not a possible 
way to remove LPS from our samples, as acid hydrolysis would change the 
polysaccharide to small fragments. Several reports had suggested that the ability 
% 
in TNF induction of natural product was related to their large molecular size. 
However, there is still no good method which could completely remove 
LPS from carbohydrate-riched samples. Polymycin B was commonly used to 
inhibit LPS activity in vitro. This antibiotic contains positively charged primary 
amines (Y-amino butyric acid) and N-terminal 6-methyl-octanoic acid. Thus, 
polymycin B could directly interact with the negatively charged pyrophosphate 
groups on lipid A by ionic interaction. Long chain fatty acid on lipid A also 
interacts with the hydrophobic region on polymycin B by hydrophobic interactions 
(Morrison et al, 1976). The presence of highly positively charged group on 
polymycin B might also interact non-specifically with the negatively charged 
polysaccharides in sample being studied. But, polymycin B was toxic with in vivo 
usuage. Thus, it was impossible to use polymycin B to inhibit LPS activity in the 
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Study of endogenous TNF production. 
Inagawa et aV (1992) reported the presence of LPS in various plant 
samples. The LPS content in Bupleuri radix hot extract (5h at 60®C) was 40Mg/g 
(of sample weight) and SO^g/g in Panax ginseng (Korea). This LPS content was 
expressed as the content of Limulus positive substances in each sample. The LPS 
content in these two samples were very low to induce significant TNF release. In 
this project, both of the Bupleuri radix md Panax quinquefolium hot extract were 
fractionated by stepwise alcohol precipitation, and fraction I being studied was 
extracted at 71.3% of alcohol concentration. The hydrophobicity of LPS made it 
not possible to be precipitated in this fraction. Moreover, the alcohol precipitation 
and dialysis were performed at 4。C，as soon as the fraction being collected from 
chromatogrphy, the fraction was lyophilized to avoid bacterial growth. Thus, LPS 
contamination could be avoided in the preparation of sample. The capacity of 
BRIB and PQIC in endogenous TNF production was related to carbohydrate and 
uronic acid content, and high molecular weight. 
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Chapter 9 Antitumor activities of BRI subfractions 
in relationship with TNF production 
9.1 BRI subfraction as eliciting agent 
EAT bearing mice recieved 2mg of BRIAa，lAb, IBa, or IBb, or 25Mg of 
LPS by iv injection on day 7. After 90min，mice were bled to collect serum for 
TNF activity determination, ascitic fluid was collected simutaneously. For a futher 
2 day, total EAT cell number in each mouse was counted with a hemocytometer 
by trypan blue exclusion method. 
LPS was applied as a positive control. It could cause a 49% suppression 
in EAT cell population (Fig 9.1). There was detectable TNF activity in serum and 
ascitic fluid, 1052±152 units/ml and 2706±457 units/ml respectively (Table 9.1). 
Among these subfractions, BRIBa and BRIBb could mediate about 50% 
suppression in EAT cell number (Fig 9.1). After 90min of sample injection, there 
was detectable TNF activity in serum, 1630±371 units/ml for BRIBa, and 1259 
units/ml for BRIBb (Table 9.1). There was negligible amount of TNF activity 
present in the ascitic fluid. BRIAa and BRIAb could also mediate a 30% 
suppression in EAT cell growth. There were 585 units/ml and 398 units/ml of 
serum TNF activity in mice treated with BRIAa and lAb respectively, but there 
was no detectable amount of TNF present in ascitic fluid. These serum TNF 
activity mediated by BRI samples in EAT bearing mice were correlated to that 
in normal mice. Also, BRIB subfractions inducing higher serum TNF activity had 
mediated the greater extent in EAT cell growth suppression. 
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Figure 9.1 Anti-tumor effect of BRIA and BRIB subfractions on EAT bearing 
mice. On day 0’ 2x10^ EAT cells was inoculated ip into ICR mice (10 in group). 
On day 7，2mg of BRIAa, lAb, IBa，or IBb, or 25Mg of LPS was injected iv. After 
90min，serum and ascitic fluid was collected simultaneously (3 per group) for TNF 
activity determination. On day 9, the remaining mice were killed, and total EAT 
cell number was counted by trypan blue exclusion method with use of a 
hemocytometer. 
The percentage value indicated the percentage of EAT cell growth suppression, 
compared with the control group. 
• 
、 
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Table 9.1 TNF titer in serum and ascitic fluid of EAT bearing mice treated 
with BRI subfractions 
treatment serum ascitic fluid 
BRIAa a 585 32 
BRIAb b 398 ND 
BRIBa c 1630 100 
BRIBb d 1259 ND 
LPS e 1052 土 152 2706 土 457 
On day 0’ each ICR mouse was inoculated with 2x10^ EAT cells ip. On day 7， 
2mg of BRI subfractions (a-d), or 25Mg of LPS (e) were injected iv into EAT 
bearing mice. After 90min, blood was drawn to collect serum, and ascitic fluid was 
collected simultaneously. TNF activity in serum and ascitic fluid were determined 
in vitro L929 assay. 
ND, undetectable. 
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Both of the LPS and BRI subfractions sample were administered by 
intravenous route, but* only mice treated with LPS had detectable TNF activity in 
ascitic fluid. The mechanism of LPS and BRI sample in endogenous TNF 
production in tumor bearing mice might be different. Royall etal (1989) reported 
that TNF and interleukin-1 (IL-1) could increase vascular endothelial cell 
monolayer permeability in the presence of serum. This changes in permeability 
could allow lipid-insoluble macromolecules to pass through. In a tumor-bearing 
mice, the immune system was primary activated against tumor. With LPS 
challenge, there might be small amount of TNF and IL-1 released into the serum 
by blood monocytes initially. After exposure to TNF and IL-1, vascular 
endothelial permeability was changed. Thus, LPS-LBP complexes were allowed 
to pass through the vascular endothelial cell to the peritoneal cavity to bind to 
CD 14 marker on peritoneal macrophage, resulting in macrophage activation and 
TNF production. TNF activity was then detected in ascitic fluid. LPS had its 
specific LPS-binding protein (LPB) to function as an opsonin for it to bind on 
monocytes/macrophages’ resulting in macrophage activation. The mechanisms for 
BRI sample in TNF induction were unknown. 
Although there was no detectable TNF activity in the ascitic fluid after iv 
injection of BRI sample, BRIBa and BRIBb could suppress EAT cell growth by 
51% and 47% respectively, nevertheless BRIAa and BRIAb could only suppress 
about 30% of EAT cell growth. The suppressive effect of BRIBa and BRIBb 
could be due to the induction of serum TNF. Though BRIAa and BRIAb could 
induce low level of serum TNF activity, they could also suppress EAT growth. 
TNF, IL-1 and LPS are able to activate endothelial cells to secrete 
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adhesion molecules such as selectins, vascular cell adhesion molecule-1 (VCAM-
1)，and intracellular cell adhesion molecule-1 and 2 (ICAM-1 and ICAM-2) 
(Famqi et al, 1993). These adhesion molecules are expressed on the surface of 
endothelial cells and binds to counter receptors existing on leukocytes and 
monocytes. Cell-cell recognition allowed monocyte adhesion to endothelium, 
resulting in migration of monocytes through the vascular endothelium to 
inflammatory or cancer site along the concentration gradient of chemotactic 
factors. Monocytes were differentiated to be macrophages in tissue site. The 
expression of adhesion molecules on endothelium required 30min for selectin, and 
6 to lOh (for VCAM-1, ICAM-1 and 2) to reach a maximum level of expression. 
Although BRI subfractions could mediate serum TNF activity after 90min of 
injection, this time period was not long enough to mediate macrophage 
recruitment in cancer site, As a result, there was no detectable TNF activity in 
ascitic fluid. 
However, the expression of adhesion molecules usually persists for 24 to 
48h, the recruitment of macrophage enhanced the antitumor activity in cancer 
sites. Macrophages infiltrated into neoplasms to mediate its tumoricidal activity. 
Martinet et al (1991) reported that there was a concentration gradient of 
chemotactic factors, which were produced by the cancer cells, between the tumor 
site and blood vessel. This in turn allowed blood monocytes to be recruited to 
tumor site. The presence of transmembrane TNF on the surface of tumor 
infiltrated macrophages (TIM) facilitated the cell-cell interaction between TIM 
and neoplastic cells. TIM could also mediate its tumoricidal activity by production 
of cytokines (TNF, IL-1, IL-6), reactive oxygen intermediates (such as OH', 
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H2O2), and antibody-dependent cellular cytotoxicity (ADCC). 
9.2 Pretreated with BRIA subfractions followed by LPS treatment 
EAT bearing mice were pretreated with 5mg of BRIAa, BRIAb, or PBS 
intraperitoneally on day 1. On day 7，mice were challenged with 25/xg of LPS. 
After LPS injection, serum and ascitic fluid were collected to determine TNF 
activity. 
Mice treated with LPS alone had 33% suppression in EAT cell growth. 
Those pretreated with BRIAa and BRIAb followed by LPS challenge had 58% 
and 57% of EAT cell suppression (Fig 9.2). EAT cell growth suppression was 
significantly enhanced when mice were pretreated with BRIAa or BRIAb. There 
was an increase in TNF activity (2239 units/ml in serum, 4467 units/ml in ascitic 
fluid) as compared with LPS control (Table 9.2). In these EAT bearing mice, 
BRIAb could enhance the LPS-induced TNF production. Pretreatment of 
peritoneal macrophage with BRIAb might activate macrophage to release TNF 
and IL-1, resulting in recruitment of blood monocytes to tumor site. As a result, 
the antitumor activity and TNF production in ascitic fluid were enhanced. 
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Figure 9.2 Anti-tumor effect of BRIA subfractions pretreatment on EAT 
bearing mice. On day 0，2x10^  EAT cells was inoculated ip into ICR mice (10 in 
group). On day 1，5mg of BRIAa, lAb，or PBS was injected ip. 25fig of LPS was 
injected iv on day 7. After 90min, serum and ascitic fluid was collected 
simultaneously (3 per group) for TNF activity determination. On day 9，the 
remaining mice were killed, and total cell number was counted by trypan blue 
exclusion method with use of a hemocytometer. 
The percentage value indicated the percentage of EAT cell growth suppression, 
compared with the control group. 
* p<0.05, compared with LPS control. 
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Table 9.2 TNF titre in serum and ascitic fluid of BRIA subfractions 
pretreated EAT bearing mice 
treatment serum ascitic fluid 
BRIAa - LPS ^ 158 2512 
BRIAb-LPS b 2239 4467 
LPS c 897 ± 103 2081 土 1081 
On day 0，each ICR mouse were inoculated with 2x10^ EAT cells ip (10 per 
group). On day 1，5mg of BRIAa(a) or BRIAb(b), or PBS(c) was injected ip into 
mice. On day 7，25/xg of LPS was injected iv into the mice. After 90min of LPS 
injection, mice were bled to collect serum, and ascitic fluid was collected 
simultaneously. TNF titre was determined by in vitro L929 assay. 
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Mice treated with BRIAa or BRIAb, without LPS challenge, could also 
mediate a 35% and 44% of EAT cell suppression respectively. This result 
suggested that BRIAa and BRIAb alone might also mediate antitumor activity. 
These samples might activate recmitment of macrophage in tumor site, and 
activate the immune system involving other immunoregulatory cells, such as T 
lymphocytes and B lymphocytes. T lymphocytes might be activated to release IFN-
Y, a potent primer for macrophage activation. Once macrophage were primed by 
IFN-Y, the cells became responsive to have elevated chemotaxis and phagocytosis, 
and responsive to low amount of LPS for TNF production and tumoricidal 
activity. 
Enhancement of LPS-induced TNF release was seen in EAT bearing mice 
pretreated with BRIAb, but not in normal mice. In this antitumor experiment, 
mice were pretreated with BRIAb intraperitoneally for 7days. In the study using 
normal mice, mice were pretreated ip for 2 days. A longer period of BRIAb 
pretreatment might be required for peritoneal macrophage to reach the primed 
stage. The potency for a sample to mediate a primed stage of macrophage 
depended on the route of sample administration (iv or ip) and the period of 
pretreatment. As mentioned in Chapter 1，there are three types of primer, 
requiring different period of pretreatment to mediate the optimal sensitivity of 
macrophage to produce TNF under stimulation by eliciting agent. However, the 
regulation of immunoregulatory cells in tumor bearing animal system and in 
normal system are different. 
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Chapter 10 Conclusion 
Both of the Bupleuri radix and Panax quinquefolium being studied were 
polysaccharide-riched. After gel filtration chromatography oi Bupleuri radix and 
Panax quinquefolium，BRIB and PQIC could trigger a higher TNF release into 
serum. BRIB had an estimated molecular weight of 20-30kD, and PQIC was 
about 4kD. Both of them were rich in uronic acid. These samples were then 
purified by DEAE-Sephadex chromatography, the negatively charged 
polysaccharides were found to be the most potent part of sample in TNF 
induction. PQICb contained much higher uronic acid content than BRIBb, while 
they had a similar potency in TNF induction. Uronic acid might participate in the 
mechanism of TNF induction, but may not be the only component involved. 
Recently, uronic acid polymers, polymannuronic acid (poly M) was found to be 
able to induce TNF production in vitro (Espevik et al, 1993). Poly M could bind 
to CD 14 on monocyte in the presence of serum. Antibodies against CD14 
inhibited the TNF production from monocytes. As compared with LPS, uronic 
acid polymers being tested were 100-1000 times less potent than LPS in TNF 
production by monocytes. However, this report demonstrated that uronic acid 
polymers could induce TNF production and CD14 was involved. 
Although PQICb contained higher uronic acid content (99.6 ±4.6%) than 
BRBBb p8.0±1.4%)，PQIC having higher uronic acid content did not trigger 
much higher serum TNF activity. BRIBb had a larger molecular weight than 
PQICb. Thus, molecular size of samples would also be important in the 
mechanism of TNF induction. 
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Mannose present in polysaccharide might also be important in macrophage 
activation. Mannose binding protein (MBP) was isolated from serum of rabbits 
(Kawasaki et al, 1978). It is an acute phase protein sythesized by the liver, similar 
to the other acute phase protein, LBP. MBP binds to mannose-riched glycan on 
the surface of bacteria and yeasts. The presence of MBP could enhance the 
binding and uptake of bacteria by polymorphonuclear leukocytes (PMN) and 
monocytes. Thus functions of MBP in the serum is to mediate recognition and 
killing of mannose-riched pathogens by neutrophils and monocytes (Kuhlman et 
al, 1989). … 一 
Another receptor for mannose-riched glycan is macrophage-specific 
mannose receptor (MR). This receptor is expressed on tissue macrophage but not 
on circulating phagocytes. It recognizes mannose-riched glycan expressed on 
bacteria, yeasts, and fungi. Both of the MBP and MR are important in mediating 
macrophage phagocytosis, but they function at different sites (Kuhlman et al, 
1989). 
Macrophage phagocytosis is a kind of macrophage activation, associated 
with cytokine production (e.g. IL-1, IL-6, TNF). Thus, mannose-riched 
polysaccharide might be able to activate macrophage in TNF production. 
However, the carbohydrate compositions in BRI and PQI sample were not 
defined. Up to date, it could not be concluded whether the endogenous TNF 
induction triggered by BRI and PQI sample was related to mannose residues. 
Further studies on the carbohydrate compositions in these polysaccharide-riched 
samples would be required. 
LPS contamination was an important problem in studing carbohydrate 
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extract of plant origin. During the preparation of sample, alcohol precipitation 
and dialysis was performed at 4°C, the sample fraction was lyophilzed as soon as 
the chromatography completed. This could avoid bacterial and fungal growth in 
the sample. Fraction I of BR being studied was obtained at alcohol concentation 
of 71.3%, at this alcohol concentration LPS might rarely be precipitated out. 
Acetic acid treatment was employed to remove LPS from sample. Lipid A 
of LPS was precipitated out under acid hydrolysis. It was bacause the KDO-lipid 
A linkage was acid labile. Carbohydrate linkages of Bupleuri radix and Panax 
quinquefolium might also be hydrolysed by acid and this was evidenced by the 
decrease in carbohydrate and uronic acid content after acetic acid treatment. 
Polysaccharides being studied might be hydrolyzed into smaller molecules. The 
change in molecular size would affect the capacity in TNF production. Thus, 
acetic acid treatment was not the perfect method in LPS removal from our 
samples. 
Acidic polysaccharides from Bupleuri radix (BRIAb) and Panax 
quinquefolium (PQIAb) having larger molecular size of 60kD were studied in 
order to study whether larger molecule could mediate priming activity on 
macrophage TNF induction. Since both the BRIAb and PQIAb could trigger TNF 
production by macrophage activation, macrophage might become refractory after 
initial activation and was non-responsive to a second stimulus, LPS. In our studies, 
the LPS-induced TNF production was initially suppressed by BRIAb or PQIAb 
pretreatment. However, the refractory state might be reversible depending on the 
sample being used (Fig 7.2). 
The suppression of LPS-induced TNF production might also be due to the 
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blockage of monocyte/macrophage LPS receptor by samples. When LPS was 
administered iv, LPS bound to LBP specifically. The complexes then bound to 
CD 14 on monocyte/macrophage, resulting in macrophage activation, and futher 
TNF production. Samples being tested might bind to CD 14 by carbohydrate 
recognition, and thus inhibit LPS-LBP complex binding onto the cell. LPS-induced 
macrophage activation was then abolished. The suppressive effect was larger when 
the samples were administered by intravenous route. 
However, among the samples being studied, BRIBb and PQICb could act 
as eliciting agent in endogenous TNF production. These molecules were uronic 
acid-riched polysaccharides. 
BRIBa and BRIBb which mediated higher endogenous TNF production 
had antitumor activity against in vivo EAT cells. TNF activity was detectable in 
serum but not in ascitic fluid after 90min of sample injection. However, TNF 
might activate endothelial cells to produce adhesion molecules, enabling 
leukocytes and monocytes to bind to endothelim. Thus, monocytes could then be 
recruited to the tumor site along the concentration gradient of chemotactic factor 
produced by cancer cell. Monocytes recruited in the tissue sites would 
differentiate to be macrophages, mediating tumoricidal activity. 
In tumor bearing mice system, pretreatment with BRIAb was able to 
enhance LPS-induced TNF production in serum and ascitic fluid, whereas this 
enhancement was not observed in normal mice system. The enhancement in LPS-
induced TNF production was correlated to the enhancement in EAT cell growth 
suppression. Pretreatment of macrophage at tumor site by BRIAb might enhance 
the recruitment of macrophage from blood monocytes, and chemotaxis of 
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macrophages to tumor site. 
Although it was evidenced that polysaccharide having large molecular size 
(100-200kD) were potent primers for endogenous TNF production (Sakagami et 
al, 1992)，BRIA and PQIA having estimated molecular size of 60kD failed to act 
as primer for endogenous TNF production. The optimal priming activity of 
macrophage was produced depending on the interval period between 
administration of priming and eliciting agents, and the route of administration. 
The present data suggested that iv administration of BRIAb or PQIAb could 
effectively suppress LPS-induced TNF release. 
TNF activity induced by 2mg of PQICb or BRIBb in normal mice was only 
2 ng/ml, nevertheless high serum TNF level might not be good for animals. High 
dose of TNF administration would mediate inflammatory response, such as 
production of reactive oxygen intermediates (e.g. CV，H.O,), nitric oxide, resulting 
in tissue damage. The release of prostaglandin E�would affect hypothalamus and 
induce transient fever. Weight loss and anemia are also observed. Thus, acute 
release of TNF may cause septic shock and tissue injury. 
Exogenous TNF injection are used in some cancer therapy, but repeated 
injections of TNF resulted in "tolerance" to TNF induction. It was because TNF 
itself is able to activate macrophage to amplify TNF production. This TNF 
tolerance might also desensitize macrophage, similar as LPS tolerance. In cancer 
therapy with TNF, a constant low TNF activity release should be maintained 
systematically (Vassalli, 1992). 
Cancer therapy with use of Chinese medicinal herbs might be beneficial. 
Chinese medicinal herbs could restore the abnormal state of immune system to 
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a normal state. Most of the reported polysaccharide extracts from these higher 
plant could activate macrophage, T and B cells, complement system, and mediate 
anti-tumor activity (Lien et al, 1990). Endogenous TNF production at constant low 
level could facilitate the tumor destruction, with aid of macrophage tumoricidial 
activity, T and B cell activation. Chemotherapy and radiotherapy would impair 
cellular immune response. Uses of natural products or biological response 
modifiers would be useful for cancer immunotherapy. 
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